

BMJ Open

Visual dysfunction and its correlation with retinal changes in patients with Parkinson disease

Journal:	<i>BMJ Open</i>
Manuscript ID:	bmjopen-2015-009658
Article Type:	Research
Date Submitted by the Author:	06-Aug-2015
Complete List of Authors:	Polo, Vicente; Miguel Servet University Hospital, Ophthalmology Satue, Maria; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Rodrigo, Maria Jesus; Miguel Servet University Hospital, Ophthalmology Otin, Sofia; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Alarcia, Raquel; Miguel Servet University Hospital, Neurology Bambo, Maria; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Fuertes, Isabel; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Larrosa, Jose; Hospital Universitario Miguel Servet, Ophthalmology; Institute for Sanitary Research of Aragon (IISA), Pablo, Luis; Miguel servet University Hospital, Ophthalmology; Institute for Sanitary Research of Aragon (IISA), Garcia-Martin, Elena; Miguel Servet University Hospital, Ophthalmology; Institute for Sanitary Research of Aragon (IISA),
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Ophthalmology, Neurology
Keywords:	Neuro-ophthalmology < NEUROLOGY, Parkinson-s disease < NEUROLOGY, Neuro-ophthalmology < OPHTHALMOLOGY

SCHOLARONE™
Manuscripts

Visual dysfunction and its correlation with retinal changes in patients with Parkinson disease.

AUTHORS:

Polo V^{1,2}, Satue M^{1,2}, Rodrigo MJ¹, Otin S^{1,2}, Alarcia R^{2,3}, Bambo MP^{1,2}, Fuertes MI^{1,2}, Larrosa JM^{1,2}, Pablo LE^{1,2}, Garcia-Martin E^{1,2}.

AFFILIATIONS:

- ¹ Ophthalmology Department, Miguel Servet University Hospital, Zaragoza, Spain.
- ² Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain.
- ³ Neurology Department, Miguel Servet University Hospital, Zaragoza, Spain.

CORRESPONDENCE:

Maria Satue
C/ Padre Arrupe. Consultas Externas de Oftalmología 50009-Zaragoza (Spain)
Email: mariasatue@gmail.com Telephone: 0034.976.76.55.58

RUNNING TITLE: OCT and visual dysfunction in Parkinson disease

KEY WORDS: Parkinson disease, visual function, contrast sensitivity, ganglion cell layer.

WORD COUNT: 2500 words.

All subjects provided detailed consent to participate in this study, which was conducted in accordance with the guidelines established by the Ethics Committee of the Miguel Servet Hospital and based on the principles of the Declaration of Helsinki.

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

The authors disclose no conflict of interest.

SUBTITLE: Visual acuity, contrast sensitivity vision and color vision are affected in Parkinson disease. Visual dysfunction in these patients correlates with structural changes in the retina measured with Spectral domain OCT.

For peer review only

Abstract

Aim: To evaluate visual dysfunction and its correlation with structural changes in the retina in patients with Parkinson disease (PD).

Methods: Patients with PD (n=37) and controls (n=37) underwent visual acuity (VA), color vision (using the Farnsworth and L'Anthony desaturated D15 color tests), and contrast sensitivity vision (CSV; using the Pelli Robson chart and CSV 1000E test) evaluation to measure visual dysfunction. Structural measurements of the retinal nerve fiber layer (RNFL), and macular and ganglion cell layer (GCL) thicknesses were obtained using spectral domain optical coherence tomography (SD-OCT). Comparison of obtained data and correlation analysis between functional and structural results were performed.

Results: VA (in all different contrast levels) and all CSV spatial frequencies were significantly worse in PD patients than in controls ($P < 0.05$). Color vision was significantly affected ($p < 0.05$) based on the L'Anthony color test. Macular thinning was detected in the central, outer (inferior and temporal), and superior sectors ($p < 0.05$), and the RNFL had significant thinning in the temporal quadrant ($p < 0.05$). Significant GCL loss was observed in the superior and superonasal sectors and the GCL + minimum inner plexiform layer ($p < 0.05$). CSV was the functional parameter most strongly correlated with structural measurements in PD. Color vision was associated with most GCL measurements. Macular thickness was strongly correlated with macular volume and functional parameters ($r > 0.70$, $p < 0.05$).

Conclusions: Patients with PD had visual dysfunction that correlated with structural changes evaluated by SD-OCT. Macular and GCL measurements may be reliable indicators of visual impairment in PD patients.

Strengths and limitations of this study:

The present study provides further information on visual dysfunction in Parkinson disease (PD) patients and corroborates previously published results on this subject. In our study the parameters corresponding to visual acuity (VA), color vision (CV) and contrast sensitivity vision (CSV) were altered in PD patients, and CSV correlated with most of the structural data. We detected significant reductions in the macular, the retinal nerve fiber layer (RNFL), and the ganglion cell layer (GCL) thicknesses. The GCL correlated most with the visual function parameters.

We consider the sample size to be the most important limitation of this study. The small number of patients may have affected the significance of our results compared to previous studies; however, we detected significant reductions in the macular, RNFL, and GCL thicknesses (consisting with previous published results).

The strengths of this study should be resumed by the following points:

- We detected alteration in VA (at different contrast levels), CSV and CV in PD patients. CSV correlated with most of the structural data.
- We detected significant reductions in the macular, RNFL, and GCL thicknesses. The GCL correlated most with the visual function parameters.
- There are only 2 other published articles evaluating the association between visual dysfunction and morphologic parameters. Results provided by these previous studies differ from our results, possibly due to different measurement methods and sample size.
- CV in our study was assessed by L'Anthony's and Farnsworth D15 color tests, which may provide more specific information about color deficiencies. These tests are not commonly used to evaluate color deficiencies in PD patients.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- Macular thickness and macular volume were strongly associated with functional parameters. This is the first study demonstrating strong correlation between structural and functional visual parameters in PD patients.

For peer review only

Introduction

Foveal vision alterations are associated with Parkinson disease (PD), and seem to be caused by dysfunction of the intraretinal dopaminergic circuitry and final retinal output to the brain.[1] Recent studies demonstrated retinal thinning in PD patients compared with healthy subjects.[2-5] Several studies report a correlation between functional disability and axonal loss observed in the optic nerve in multiple sclerosis, another neurodegenerative process.[6,7] PD patients are also reported to have decreased contrast sensitivity and color vision, and altered visual evoked potentials.[1,8-13] To our knowledge, however, very few studies have assessed visual dysfunction in PD and its correlation with morphologic parameters.[14,15]

In the present study, we evaluated visual acuity (VA) using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart, contrast sensitivity vision (CSV) using the CSV-1000E test and Pelli-Robson chart, and color vision using the Farnsworth and L'Anthony tests in PD patients and healthy controls to examine the association between visual dysfunction and morphologic parameters.

Material and methods

Thirty-seven eyes of 37 patients with definite PD and 37 eyes of 37 age- and sex-matched healthy individuals were recruited for the study. The study was performed at Miguel Servet University Hospital in Zaragoza, Spain. All procedures adhered to the tenets of the Declaration of Helsinki, and all participants provided informed consent to participate in the study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The diagnosis of PD was based on standard clinical and neuroimaging criteria.[16] Information about disease severity was assessed using the Hoehn Yahr scale,[17] and disease duration and treatment were recorded. Exclusion criteria were the presence of significant refractive errors (>5 diopters of spherical equivalent refraction or 3 diopters of astigmatism); intraocular pressure ≥ 21 mmHg; media opacifications; concomitant ocular diseases, including history of glaucoma or retinal pathology; and systemic conditions that could affect the visual system. The healthy controls had no history and no evidence of ocular or neurologic disease of any nature; their best-corrected visual acuity (BCVA) was $>20/30$ based on the Snellen scale.

All subjects underwent a complete neuro-ophthalmic evaluation that included pupillary, anterior segment, and funduscopy examination. Visual function was assessed by evaluating BCVA using an ETDRS chart, CSV using the CVS-1000E test and Pelli-Robson chart, and color vision using the Farnsworth desaturated D15 and L'Anthony desaturated D15 tests. Structural analysis of the retina was performed using Spectral domain (SD) optical coherence tomography (OCT) with the Cirrus High definition (HD) OCT (Carl Zeiss Meditec Inc, Dublin, CA), which included three different protocols: macular protocol (for macular thickness analysis), RNFL protocol, and ganglion cell protocol (for individual analysis of this layer).

LogMAR visual acuity (VA) was evaluated at three different contrast levels: 100% (HCVA, using ETDRS chart), 2.50%, and 1.25% (LCVA, using Low-Contrast Sloan Letter Charts - Precision Vision, LaSalle, IL-), The percentage indicating the level of contrast, i.e., 100% representing black letters over white background and 1.25% light grey letters over white background. All measurements were obtained under monocular vision and controlled lighting conditions with best correction.

Contrast sensitivity provides more complete information about visual function than visual acuity tests. CSV was evaluated in our patients using the Pelli-Robson chart and the CVS-1000E test.

The Pelli-Robson chart comprises horizontal lines of capital letters organized into groups of three (triplets) with two triplets per line. Within each triplet, all letters have the same contrast.

The contrast decreases from one triplet to the next, even within each line. All patients were evaluated under both monocular and binocular vision at a distance of 1 meter from the chart and under controlled photopic conditions (85 cd/m^2). The score corresponding to the last triplet of letters seen by the patient was recorded.

The CVS-1000E instrument is used worldwide for standardized CSV and glare testing. All patients were evaluated at a distance of 2.5 meters from the chart under monocular vision at 4 different spatial frequencies (3, 6, 12, and 18 cycles per degree [cpd]). The chart comprises four rows with 17 circular patches each. The patches present a grating that decreases in contrast moving from left to right across the row. The patient indicates whether the grating appears in the top patch or the bottom patch for each column. Each contrast value for each spatial frequency was transformed into a logarithmic scale according to standardized values.

Color vision was assessed using the Color Vision Recorder (CVR) program. CVR software analyzes chromatic discrimination by classification of colors. The program includes the classic test of Farnsworth 100-hue (FM-100), Farnsworth - Munsell D15, and L'Anthony D15. All patients in the study were evaluated using the Farnsworth - Munsell D15 and L'Anthony D15 protocols and different output parameters such as the Confusion Index (C-index), the Color Confusion Index (CCI), the Confusion angle (Conf Ang), and the Scatter Index (S-index) were recorded.^{18,19} The tests were performed under monocular vision.

Structural measurements of the retina were obtained using the Cirrus OCT device. The same experienced operator performed all scans and did not apply manual correction to the OCT output. We used an internal fixation target because it provides the highest reproducibility and rejected poor quality scans prior to data analysis. The Cirrus OCT macular cube 512 x 128 protocol provides a macular volume measure and retinal thickness values for nine areas. These areas include a central 1-mm circle representing the fovea, and inner and outer rings measuring 3 mm and 6 mm in diameter, respectively. The inner and outer rings are divided into four quadrants each. The Cirrus OCT optic disc protocol generates images with 200 linear scans enabling analysis of the RNFL of a 6-mm³ area around the optic nerve. For each scan series of RNFL measurements, we assessed the mean, superior, inferior, temporal, and nasal thickness. Cirrus segmentation analysis for retinal layers also provides measurements of the GCL thickness, evaluating six areas of the macular cube (superior, superonasal, inferonasal, inferior, inferotemporal, and superotemporal sectors) and measurements of the mean and minimum GCL plus the inner plexiform layer (GCL + IPL) value of a set of 360 spokes, where each average represents the mean number of the pixels along that spoke that lies within the measurement annulus. The minimum is selected because the thinnest portion of the GCL + IPL in the perifoveal region is considered to indicate damage to the ganglion cells.

All data analyses were performed using SPSS software version 20.0 (SPSS Inc., Chicago, IL). Due to the parametric distribution of the data, differences between evaluations of PD patients and healthy subjects were compared using Student's t-test. The linear correlation between structural and functional parameters was determined using Pearson's correlation coefficient. Values of $p < 0.05$ were considered to indicate statistical significance. Each eye was considered separately, and one eye from each patient was randomly selected for analysis.

Results

Thirty-seven patients with PD and 37 healthy controls were included in the study. The mean age of the patients with PD was 69 years (range: 58–74 years) and the mean age of the healthy controls was 68 years (range: 60–76 years). Age ($p=0.361$), sex ($p=0.441$), and intraocular pressure ($p=0.720$) did not differ significantly between healthy controls and patients with PD. Mean time from diagnosis of PD was 13.2 years and the median Hoehn Yahr stage was 2.7.

Functional parameters

PD patients had a lower BCVA at all three contrast levels of the ETDRS chart compared to the controls (0.18 ± 0.26 in patients vs -0.065 ± 0.9 in controls at 100%, $p=0.001$; 0.59 ± 0.21 vs 0.44 ± 0.13 at 2.50%, $p=0.01$; and 0.61 ± 0.23 vs 0.58 ± 0.16 at 1.25%, $p=0.009$). CSV was affected in patients at all four spatial frequencies of the CSV 1000E chart (3, 6, 12, and 18 cpd) when analyzed based on the number of correct localized gratings ($p=0.001$, <0.001 , <0.001 , and 0.004 respectively). The Pelli Robson results also revealed a significant reduction in CSV in PD patients (1.71 in patients vs 1.89 in controls, $p=0.02$). Color vision (L'Anthony test indexes) was also affected in PD. The results are shown in Table 1.

	HEALTHY CONTROLS		PARKINSON DISEASE PATIENTS		SIGNIFICANCE (P)
	Mean	SD	Mean	SD	
VA ETDRS 100	-0.06	0.096	0.18	0.26	0.001
VA ETDRS 2.5	0.44	0.13	0.59	0.22	0.010
VA ETDRS 1.25	0.58	0.16	0.62	0.23	0.009
Pelli Robson	1.89	0.11	1.71	0.17	0.002
CSV 1000 3 cpd	1.72	0.16	1.49	0.35	0.001
CSV 1000 6 cpd	1.94	0.13	1.62	0.34	0.000
CSV 1000 12 cpd	1.62	0.17	1.26	0.41	0.000
CSV 1000 18 cpd	1.11	0.22	0.73	0.34	0.004
Farnsworth AC CCI	1.11	0.22	0.73	0.34	0.851
Farnsworth C- index	1.10	0.20	1.24	0.42	0.093
Farnsworth CCI	1.07	0.12	1.14	0.24	0.110
Farnsworth Conf Angle	63.90	11.15	65.84	7.49	0.392
Farnsworth S-index	1.56	0.22	1.64	0.39	0.278
Farnsworth time	78.67	28.96	82.91	33.10	0.616
L'Anthony AC CCI	1.05	0.19	1.02	0.18	0.489
L'Anthony C-index	1.43	0.39	1.64	0.53	0.058
L'Anthony CCI	1.30	0.23	1.44	0.37	0.066
L'Anthony Conf Angle	62.31	14.74	71.91	9.25	0.002
L'Anthony S-index	1.69	0.43	1.95	0.48	0.020
L'Anthony time	77.14	25.99	84.09	39.31	0.431

Structural parameters

OCT measurements indicated significant differences in superior macular sectors, in the outer inferior, outer temporal, and central macular thickness (results are shown in Table 2, Figure 1). The segmentation analysis revealed a significantly reduced GCL in PD patients in the superior ($81.64 \pm 7.08 \mu\text{m}$ in patients vs $84.55 \pm 4.32 \mu\text{m}$ in controls; $p=0.032$) and superonasal sectors ($81.04 \pm 7.23 \mu\text{m}$ vs $85.28 \pm 4.78 \mu\text{m}$; $p=0.029$). The minimum GCL+IPL value was also reduced ($80.18 \pm 6.19 \mu\text{m}$ vs $82.45 \pm 3.60 \mu\text{m}$; $p=0.005$). The RNFL was significantly reduced in the temporal quadrant in PD patients (Table 2, Figure 1).

	CONTROLS		PARKINSON DISEASE		
Structural parameters	Mean	SD	Mean	SD	P
<i>Macular measurements</i>					
Central macular thickness	254.75	17.903	248.96	17.765	0.028
Inner superior macular thickness	327.34	13.094	325.73	19.329	0.019
Inner nasal macular thickness	328.52	13.263	325.45	17.098	0.091
Inner inferior macular thickness	326.14	13.179	324.82	17.921	0.106
Inner temporal macular thickness	315.90	13.615	312.82	15.760	0.945
Outer superior macular thickness	284.76	9.418	279.44	17.981	0.008
Outer nasal macular thickness	302.41	12.167	299.18	17.064	0.074
Outer inferior macular thickness	277.79	10.755	273.76	16.798	0.045
Outer temporal macular thickness	271.52	10.992	266.23	18.987	0.013
<i>Ganglion cell layer thickness</i>					
Superior	84.55	4.323	81.61	7.087	0.032
Superonasal	85.28	4.780	81.04	7.234	0.029
Inferonasal	84.66	5.314	81.82	7.521	0.135
Inferior	84.34	5.052	81.91	6.252	0.389
Inferotemporal	85.79	4.003	83.73	4.860	0.233
Temporal	83.76	3.324	82.27	5.312	0.069
Average IPL+GCL	84.83	4.071	82.73	6.230	0.095
Min IPL+ GCL	82.45	3.601	80.18	6.194	0.005
<i>RNFL thickness</i>					
Average	96.17	6.714	94.88	11.505	0.105
Superior	117.90	10.965	118.68	16.861	0.115
Nasal	73.59	12.724	72.40	15.182	0.345

Inferior	128.14	14.060	123.20	22.907	0.075
Temporal	64.97	8.218	61.48	10.553	0.027

Correlation between functional and structural parameters

CSV was the functional parameter most frequently associated with structural measurements in PD. The Pelli Robson CSV results correlated with GCL thickness in all sectors, although the association was not strong ($r < 0.5$). The superonasal ($r=0.40$, $p=0.010$), inferonasal ($r=0.40$, $p=0.010$), inferior ($r=0.43$, $p=0.005$), superotemporal sector ($r=0.43$, $p=0.006$), and mean GCL+IPL ($r=0.45$, $p=0.004$) values had the highest correlations. The Pelli Robson results also correlated with the thickness in different sectors of the RNFL (mean, superior, and inferior sectors). Measurements with the CSV 1000E at different spatial frequencies correlated significantly with most GCL measurements. The superonasal ($r= 0.40$, $p= 0.013$) and superotemporal ($r= 0.44$, $p= 0.006$) thickness, mean GCL +IPL thickness ($r= 0.40$, $p= 0.012$), and the minimum GCL + IPL ($r= 0.40$, $p=0.011$) at a spatial frequency of 6 cpd; and the superotemporal ($r= 0.41$, $p= 0.01$) thickness and the minimum GCL + IPL thickness ($r= 0.43$, $p=0.006$) at a spatial frequency of 18 cpd had the strongest correlations between CSV 1000E and GCL thickness. Spatial frequencies of 6 cpd and 18 cpd were strongly correlated with mean macular thickness ($r= 0.79$, $p= 0.012$; $r= 0.77$, $p= 0.016$, respectively) and macular volume ($r= 0.78$, $p= 0.013$; $r= 0.78$, $p= 0.014$, respectively).

Color vision assessed by the L’Anthony test was also associated with the structural parameters: both the L’Anthony CCI and C-index values were significantly correlated with most of the GCL measurements (see Table 3). A significant association between color vision and the RNFL parameters was only found in isolated sectors. All outer macular parameters were significantly correlated with the L’Anthony CCI and C-index results (see Table 3).

	L'Anthony's color test					
	C-index	p	CCI	p	S-index	p
Macular thickness						
Central	-0.019	0.905	-0.059	0.716	-0.017	0.915
Inner superior	-0.146	0.369	-0.119	0.463	-0.167	0.302
Inner nasal	-0.055	0.735	-0.044	0.788	-0.040	0.807
Inner inferior	-0.073	0.654	-0.064	0.697	-0.074	0.649
Inner temporal	-0.049	0.764	-0.031	0.850	-0.126	0.439
Outer superior	-0.377	0.017	-0.380	0.015	-0.271	0.090
Outer nasal	-0.341	0.031	-0.323	0.042	-0.310	0.051
Outer inferior	-0.360	0.022	-0.353	0.025	-0.375	0.017

The strongest correlation was between the mean macular thickness and macular volume and the L'Anthony CCI, C-index, and S-index results. No significant correlations were found between the Farnsworth's test parameters and structural measurements.

Outer temporal	-0.360	0.023	-0.361	0.022	-0.350	0.027
Macular average	-0.691	0.019	-0.657	0.028	-0.709	0.015
Macular volume	-0.686	0.020	-0.647	0.032	-0.709	0.015
Ganglion cell layer thickness						
Superior	-0.380	0.015	-0.369	0.019	-0.287	0.072
Superonasal	-0.383	0.015	-0.337	0.033	-0.350	0.027
Inferonasal	-0.338	0.033	-0.313	0.049	-0.268	0.094
Inferior	-0.341	0.031	-0.311	0.051	-0.282	0.078
Inferotemporal	-0.252	0.116	-0.263	0.101	-0.203	0.208
Temporal	-0.403	0.010	-0.437	0.005	-0.314	0.048
Average IPL+ GCL	-0.381	0.015	-0.358	0.023	-0.319	0.045
Minimun IPL+ GCL	-0.338	0.033	-0.326	0.040	-0.290	0.069

The VA ETDRS results correlated strongly with mean macular thickness and macular volume (see Table 4). There were significant but mild associations between the GCL parameters and VA at 100% (superonasal, inferonasal, and mean GCL + IPL thickness, $r=-0.38$, $p=0.016$; $r=-0.35$, $p=0.016$; and $r=0.35$, $p=0.029$, respectively) and 2.50% (superonasal sector, $r=-0.36$, $p=0.023$).

	Macular thickness	P value	Macular volumen	P value
VA ETDRS 100	-0.765	0.006	-0.761	0.007
VA ETDRS 1.25	-0.718	0.013	-0.715	0.013
VA ETDRS 2.50	-0.738	0.010	-0.729	0.011

Discussion

In the present study, we evaluated the visual function parameters and assessed the association between visual dysfunction and morphologic changes in the retina of 37 patients with PD.

Parameters corresponding to VA at different contrast levels, and all CSV tests results were altered in PD patients in comparison with healthy subjects. Moreover, contrast sensitivity was the most affected parameter in our study and correlated with most of the structural data. Color vision was measured with two different tests, the Farnsworth and L'Anthony 15 D tests. These tests provide information for differentiating subjects with severe loss of color vision from those with milder color defects or normal color vision, and also can be used to evaluate acquired loss of color vision. In our study, only the L'Anthony test results were significantly altered in PD patients.

Previous studies have indicated that PD patients lose foveal contrast sensitivity to patterns to which normal observers are most sensitive (i.e., requiring the least contrast for detection).[8,9] Ganglion cells in the retina show adaptation to visual contrast and pool visual inputs over their receptive fields through an array of parallel bipolar cells with smaller receptive fields.[20] In the mammalian retina, color vision and contrast sensitivity are modulated through D1 and D2 receptors. These dopaminergic receptors are differentially located in the retinal layers and a complete lack of activation leads to signal dispersion and alterations in color vision and contrast sensitivity.[2]

Alteration of the retinal layers in PD was first demonstrated in 2004.[21] Since then, various studies have demonstrated different results.[3-5,21,22] A previous study carried out by our team suggested that macular thickness and the inner retinal layers were affected in PD patients.[23]

GCL thickness was inversely correlated with disease duration and PD severity, and predictive of axonal damage in these patients.[25] The present study included a smaller number of patients, which may have affected the significance of our results compared to previous studies. Despite the small number of subjects in the present study, however, we detected significant reductions in the macular, RNFL, and GCL thicknesses. The GCL correlated most with the visual function parameters: GCL thickness was directly associated with VA and CSV measured at all different spatial frequencies, and inversely correlated with the color vision indexes. Thus, GCL thinning is linked to color deficiencies, contrast sensitivity loss, and lower vision at different contrast levels in PD patients.

The degree of correlation is usually classified as low (<0.30), moderate ($0.30-0.70$), or strong (>0.70). Our results revealed a low and moderate degree of correlation between most parameters, consistent with findings in other neurodegenerative diseases.[24] Macular thickness and macular volume, however, were strongly associated with functional parameters (VA, CS, and L'Anthony CCI, C-index, and S-index). This strong association, to the best of our knowledge, has not been previously demonstrated in PD.

There are very few studies of the correlation between functional and structural parameters in PD patients. Adam et al [14] demonstrated a significant reduction in the inner retinal layer complex (RNFL + GCL + IPL) in PD patients, but no association with contrast sensitivity (measured with the Pelli Robson chart). A very recent study by Kaur et al [15] demonstrated a correlation between functional parameters and GCL thinning, consistent with our results. Kaur et al, however, found no significant alterations in VA or color vision in PD patients and the severity of the disease was not correlated with structural parameters, in contrast to other studies that demonstrate an association between macular and GCL thickness and disease duration and

severity.[23,25] Although the severity of the disease in our sample (based on the Hoehn Yahr scale) was similar to that in Kaur's study, the duration of the disease in our study was higher than that in Kaur's patients (13 years vs 5 years), which may account for some of the differences in the results between the two studies. These discrepancies (and similarities) support the need for more studies on this topic. Our results, together with previously published studies,[15,24] suggest that the GCL could be a reliable indicator of structural alterations in the retina of PD patients, demonstrating a significant correlation with functional tests in these patients. The results of the present study have important implications for clinical diagnosis and functional deficits in patients with PD, and highlight the importance of visual function tests in the evaluation of these patients.

In conclusion, visual dysfunction was significantly correlated with morphologic parameters in PD patients. PD patients present with a reduction in macular, RNFL, and GCL thickness, with changes in the GCL being most closely associated with visual dysfunction.

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

The authors disclose no conflict of interest.

No additional data available.

Contributorship:

V. Polo: Research project: organization. Statistical analysis and Manuscript: Review and critique.

M. Satue: Research project: Conception, design, organization and execution. Statistical analysis: Review and critique. Manuscript: Writing of the first draft, review and critique.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

MJ Rodrigo: Research project: organization and execution. Statistical analysis: Review and critique. Manuscript: Writing of the first draft, review and critique.

S. Otin: Research project: organization and execution. Statistical analysis: Review and critique. Manuscript: review and critique.

R. Alarcia: Research project: organization and execution. Statistical analysis: Review and critique. Manuscript: review and critique.

MP. Bambo: Research project: execution. Statistical analysis: Review and critique. Manuscript: review and critique.

MI. Fuertes: Research project: execution. Statistical analysis: Review and critique. Manuscript: review and critique.

JM. Larrosa: Research project: execution. Statistical analysis: Review and critique. Manuscript: review and critique.

LE. Pablo: Research project: execution. Statistical analysis: Review and critique. Manuscript: review and critique.

E. Garcia-Martin: Research project: Conception, design, organization and execution. Statistical analysis: Design, execution, review and critique. Manuscript: Writing of the first draft, review and critique.

For peer review only

References

1. Bodis-Wollner I. Retinopathy in Parkinson disease. J Neural Transm 2009;116:1493-501.

2. Hajee ME, March WF, Lazzaro DR et al. Inner retinal layer thinning in Parkinson's disease. Arch Ophthalmol 2009;127:737-41.

3. Cubo E, Tedejo RP, Rodriguez Mendez V. Retina thickness in Parkinson's disease and essential tremor. Mov Disord 2010;25:2461-77.

4. Satue M, Garcia-Martin E, Fuertes I et al. Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson's disease patients. Eye (Lond) 2013;27:507-14.

5. Garcia-Martin E, Satue M, Fuertes I et al. Ability and reproducibility of Fourier domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson's disease. Ophthalmology 2012;119:2161-7.

6. Fisher JB, Jacobs DA, Markowitz CE et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006;113:324.

7. Parisi V, Manni G, Spadaro M et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci 1999;40:2520-7.

8. Bodis-Wollner I. Visual acuity and contrast sensitivity in patients with cerebral lesions. Science 1972;178:769-71.

9. Bodis-Wollner I, Diamond S. The measurement of spatial contrast sensitivity in cases of blurred vision associated with cerebral lesions. Brain 1976;99:695-710.

10. Price MJ, Feldman RG, Adelberg D et al. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992;42:887-90.

11. Oh YS, Kim JS, Chung SW et al. Color vision in Parkinson's disease and essential tremor. *European Journal of Neurology* 2011;18: 577-83.
12. Hipp G, Diederichs NJ, Pieria V et al. Primary vision and facial emotion recognition in early Parkinson's disease. *Journal of the Neurological Sciences* 2014;338 :178-82.
13. Archibald NK, Clarke MP, Mosimann UP et al. Retinal thickness in Parkinson's disease. *Parkinsonism Relat Disord* 2011; 17(6):431-6.
14. Adam CR1, Shrier E, Ding Y et al. Correlation of inner retinal thickness evaluated by spectral-domain optical coherence tomography and contrast sensitivity in Parkinson disease. *J Neuroophthalmol.* 2013;33(2):137-42.
15. Kaur M, Saxena R, Singh D et al. Correlation Between Structural and Functional Retinal Changes in Parkinson Disease. *J Neuroophthalmol* 2015 [Epub ahead of print]
16. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. *Arch Neurol* 1999;56:33-9.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. *Neurology* 1967;17:427-42.
18. Vingrys AJ, King-Smith PE. A quantitative scoring technique for panel tests of color vision. *Invest Ophthalmol Vis Sci* 1988;29(1):50-63.
19. Bowman AJ. A method for quantitative scoring of the Farnsworth panel D15. *Acta Ophthalmologica* 1982;60:907-16.
20. Kim, KJ, Rieke, F. Temporal contrast adaptation in the input and output signals of salamander retinal ganglion cells. *J. Neurosci* 2001;21:287-99.

21. Inzelberg R, Ramirez JA, Nisipeanu P et al. Retinal nerve fiber layer thinning in Parkinson's disease. *Vision Res* 2004;44:2793-7.

22. Altıntaş O, Işeri P, Ozkan B et al. Correlation between retinal morphological and functional findings and clinical severity in Parkinson's disease. *Doc Ophthalmol* 2008;116:137-46.

23. Garcia-Martin E, Larrosa JM, Polo V et al. Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration. *Am J Ophthalmol* 2014;157(2):470-8.

24. Garcia-Martin E, Rodriguez-Mena D, Herrero R, et al. Neuro-ophthalmologic evaluation, quality of life and functional disability in MS patients. *Neurology* 2013;81:1-8.

25. Satue M, Seral M, Otin S et al. Retinal thinning and correlation with functional disability in patients with Parkinson's disease. *Br J Ophthalmol* 2014;98(3):350-5.

Legends

Figure 1: Structural parameter means of macular, ganglion cell and retinal nerve fiber layer thickness obtained with Cirrus HD coherence tomography device, comparing healthy controls and patients with Parkinson's disease. HD, high definition; GCL, ganglion cell layer; IPL, inner plexiform layer; RNFL, retinal nerve fiber layer.

Table 1: Mean and standard deviation (SD) of visual functional parameters in healthy controls and subjects with Parkinson disease. Results in bold letters indicate statistical significance ($p < 0.05$). Abbreviations: VA, visual acuity; ETDRS, early treatment diabetic retinopathy study; cpd, cycles per degree; AC CCI, age corrected color confusion index; CCI, color confusion index; C-index, confusion index; Conf Angle, confusion angle; S-index, scatter index; PD, Parkinson disease.


Table 2: Mean and standard deviation (SD) of structural parameters (retinal nerve fiber layer, ganglion cell layer and macular thicknesses) obtained with the Cirrus HD optical coherence tomography device in healthy controls and subjects with Parkinson disease. Bold letters indicate statistical significance ($p < 0.05$). Abbreviations: IPL, inner plexiform layer; GCL, ganglion cell layer; RNFL, retinal nerve fiber layer; HD, high definition.

Table 3: Correlation between macular and ganglion cell layer structural measurements and color vision evaluated with L'Anthony's color test in patients with Parkinson disease. Data in bold type correspond to statistically significant correlations (p value < 0.05). Abbreviations: GCL,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ganglion cell layer; IPL, inner plexiform layer; C-index, Confusion index; CCI, color confusion index; S-index, Scatter index.

Table 4: Correlation between visual acuity measured with ETDRS chart at different levels of contrast (in %) and macular structural measurements (thickness and volume) in patients with Parkinson disease. Correlation data in bold type are statistically significant (p value <0.05).
Abbreviations: VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.



62x30mm (300 x 300 DPI)

BMJ Open

Visual dysfunction and its correlation with retinal changes in patients with Parkinson disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-009658.R1
Article Type:	Research
Date Submitted by the Author:	20-Nov-2015
Complete List of Authors:	Polo, Vicente; Miguel Servet University Hospital, Ophthalmology Satue, Maria; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Rodrigo, Maria Jesus; Miguel Servet University Hospital, Ophthalmology Otin, Sofia; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Alarcia, Raquel; Miguel Servet University Hospital, Neurology Bambo, Maria; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Fuertes, Isabel; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Larrosa, Jose; Hospital Universitario Miguel Servet, Ophthalmology; Institute for Sanitary Research of Aragon (IISA), Pablo, Luis; Miguel servet University Hospital, Ophthalmology; Institute for Sanitary Research of Aragon (IISA), Garcia-Martin, Elena; Miguel Servet University Hospital, Ophthalmology; Institute for Sanitary Research of Aragon (IISA),
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Ophthalmology, Neurology
Keywords:	Neuro-ophthalmology < NEUROLOGY, Parkinson-s disease < NEUROLOGY, Neuro-ophthalmology < OPHTHALMOLOGY

SCHOLARONE™
Manuscripts

Visual dysfunction and its correlation with retinal changes in patients with Parkinson disease.

AUTHORS:

Polo V^{1,2}, Satue M^{1,2}, Rodrigo MJ¹, Otin S^{1,2}, Alarcia R^{2,3}, Bambo MP^{1,2}, Fuertes MI^{1,2}, Larrosa JM^{1,2}, Pablo LE^{1,2}, Garcia-Martin E^{1,2}.

AFFILIATIONS:

- ¹ Ophthalmology Department, Miguel Servet University Hospital, Zaragoza, Spain.
- ² Aragon Health Research Institute (IIS Aragon), Zaragoza, Spain.
- ³ Neurology Department, Miguel Servet University Hospital, Zaragoza, Spain.

CORRESPONDENCE:

Maria Satue
C/ Padre Arrupe. Consultas Externas de Oftalmología 50009-Zaragoza (Spain)
Email: mariasatue@gmail.com Telephone: 0034.976.76.55.58

RUNNING TITLE: OCT and visual dysfunction in Parkinson disease

KEY WORDS: Parkinson disease, visual function, contrast sensitivity, ganglion cell layer.

WORD COUNT: 2500 words.

All subjects provided detailed consent to participate in this study, which was conducted in accordance with the guidelines established by the Ethics Committee of the Miguel Servet Hospital and based on the principles of the Declaration of Helsinki.

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

The authors disclose no conflict of interest.

SUBTITLE: Visual acuity, contrast sensitivity vision and color vision are affected in Parkinson disease. Visual dysfunction in these patients correlates with structural changes in the retina measured with Spectral domain OCT.

For peer review only

Abstract

Objectives: To evaluate visual dysfunction and its correlation with structural changes in the retina in patients with Parkinson disease (PD).

Methods: Patients with PD (n=37) and controls (n=37) were included in a observational cross-sectional study and underwent visual acuity (VA), color vision (using the Farnsworth and L'Anthony desaturated D15 color tests), and contrast sensitivity vision (CSV; using the Pelli Robson chart and CSV 1000E test) evaluation to measure visual dysfunction. Structural measurements of the retinal nerve fiber layer (RNFL), and macular and ganglion cell layer (GCL) thicknesses were obtained using spectral domain optical coherence tomography (SD-OCT). Comparison of obtained data and correlation analysis between functional and structural results were performed.

Results: VA (in all different contrast levels) and all CSV spatial frequencies were significantly worse in PD patients than in controls ($P < 0.05$). Color vision was significantly affected ($p<0.05$) based on the L'Anthony color test. Macular thinning was detected in the central, outer (inferior and temporal), and superior (inner and outer) sectors ($p<0.05$), and the RNFL had significant thinning in the temporal quadrant ($p<0.05$). Significant GCL loss was observed in the superior and superonasal sectors and the minimum GCL + inner plexiform layer ($p<0.05$). CSV was the functional parameter most strongly correlated with structural measurements in PD. Color vision was associated with most GCL measurements. Macular thickness was strongly correlated with macular volume and functional parameters ($r > 0.70$, $p<0.05$).

Conclusions: Patients with PD had visual dysfunction that correlated with structural changes evaluated by SD-OCT. Macular and GCL measurements may be reliable indicators of visual impairment in PD patients.

Strengths and limitations of this study:

The strengths of this study should be resumed by the following bullet points:

- We detected alteration in VA (at different contrast levels), CSV and CV in PD patients. CSV correlated with most of the structural data.
- We detected significant reductions in the macular, RNFL, and GCL thicknesses. The GCL correlated most with the visual function parameters.
- There are only 2 other published articles evaluating the association between visual dysfunction and morphologic parameters. Results provided by these previous studies differ from our results, possibly due to different measurement methods and sample size.
- CV in our study was assessed by L'Anthony and Farnsworth D15 color tests, which may provide more specific information about color deficiencies. These tests are not commonly used to evaluate color deficiencies in PD patients.
- Macular thickness and macular volume were strongly associated with functional parameters. This is the first time such a strong correlation is reported ($r>0.70$).

Introduction

Foveal vision alterations are associated with Parkinson disease (PD), and seem to be caused by dysfunction of the intraretinal dopaminergic circuitry and final retinal output to the brain.[1] Recent studies demonstrated retinal thinning in PD patients compared with healthy subjects.[2-5] Several studies report a correlation between functional disability and axonal loss observed in the optic nerve in multiple sclerosis, another neurodegenerative process.[6,7] PD patients are also reported to have decreased contrast sensitivity and color vision, and altered visual evoked potentials.[1,8-13] To our knowledge, however, very few studies have assessed visual dysfunction in PD and its correlation with morphologic parameters.[14,15] In the present study, we evaluated visual acuity (VA) using an Early Treatment Diabetic Retinopathy Study (ETDRS) chart, contrast sensitivity vision (CSV) using the CSV-1000E test and Pelli-Robson chart, and color vision using the Farnsworth and L'Anthony tests in PD patients and healthy controls to examine the association between visual dysfunction and morphologic parameters.

Material and methods

Thirty-seven eyes of 37 patients with definite PD and 37 eyes of 37 age- and sex-matched healthy individuals were recruited for the study. The study was performed at Miguel Servet University Hospital in Zaragoza, Spain. All procedures adhered to the tenets of the Declaration of Helsinki, and all participants provided informed consent to participate in the study.

The diagnosis of PD was based on standard clinical and neuroimaging criteria.[16] Information about disease severity was assessed using the Hoehn Yahr scale [17] and the Unified Parkinson Disease Rating Scale III (UPDRS) [18]. Disease duration and treatment were recorded.

Exclusion criteria were the presence of significant refractive errors (>5 diopters of spherical equivalent refraction or 3 diopters of astigmatism); intraocular pressure ≥ 21 mmHg; media opacifications; concomitant ocular diseases, including history of glaucoma or retinal pathology; and systemic conditions that could affect the visual system. The healthy controls had no history and no evidence of ocular or neurologic disease of any nature; their best-corrected visual acuity (BCVA) was >20/30 based on the Snellen scale.

All subjects underwent a complete neuro-ophthalmic evaluation that included pupillary, anterior segment, and funduscopy examination. Visual function was assessed by evaluating BCVA using an ETDRS chart, CSV using the CVS-1000E test and Pelli-Robson chart, and color vision using the Farnsworth desaturated D15 and L'Anthony desaturated D15 tests. Structural analysis of the retina was performed using Spectral domain (SD) optical coherence tomography (OCT) with the Cirrus High definition (HD) OCT (Carl Zeiss Meditec Inc, Dublin, CA), which included three different protocols: macular protocol (for macular thickness analysis), RNFL protocol, and ganglion cell protocol (for individual analysis of this layer).

LogMAR visual acuity (VA) was evaluated at three different contrast levels: 100% (HCVA, using ETDRS chart), 2.50%, and 1.25% (LCVA, using Low-Contrast Sloan Letter Charts - Precision Vision, LaSalle, IL-), The percentage indicating the level of contrast, i.e., 100% representing black letters over white background and 1.25% light grey letters over white background. All measurements were obtained under monocular vision and controlled lighting conditions with best correction.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Contrast sensitivity provides more complete information about visual function than visual acuity tests. CSV was evaluated in our patients using the Pelli-Robson chart and the CVS-1000E test. The Pelli-Robson chart comprises horizontal lines of capital letters organized into groups of three (triplets) with two triplets per line. Within each triplet, all letters have the same contrast. The contrast decreases from one triplet to the next, even within each line. All patients were evaluated under both monocular and binocular vision at a distance of 1 meter from the chart and under controlled photopic conditions (85 cd/m²). The score corresponding to the last triplet of letters seen by the patient was recorded.

The CSV-1000E instrument is used worldwide for standardized CSV and glare testing. All patients were evaluated at a distance of 2.5 meters from the chart under monocular vision at 4 different spatial frequencies (3, 6, 12, and 18 cycles per degree [cpd]). The chart comprises four rows with 17 circular patches each. The patches present a grating that decreases in contrast moving from left to right across the row. The patient indicates whether the grating appears in the top patch or the bottom patch for each column. Each contrast value for each spatial frequency was transformed into a logarithmic scale according to standardized values.

Color vision was assessed using the Color Vision Recorder (CVR) program. CVR software analyzes chromatic discrimination by classification of colors. The program includes the classic test of Farnsworth 100-hue (FM-100), Farnsworth - Munsell D15, and L'Anthony D15. All patients in the study were evaluated using the Farnsworth - Munsell D15 and L'Anthony D15 protocols and different output parameters such as the Confusion Index (C-index), the Color Confusion Index (CCI), the Confusion angle (Conf Ang), and the Scatter Index (S-index) were recorded.[19,20] The tests were performed under monocular vision.

138 Structural measurements of the retina were obtained using the Cirrus OCT device. The same
139 experienced operator performed all scans and did not apply manual correction to the OCT
140 output. We used an internal fixation target because it provides the highest reproducibility and
141 rejected poor quality scans prior to data analysis. The Cirrus OCT macular cube 512 x 128
142 protocol provides a macular volume measure and retinal thickness values for nine areas. These
143 areas include a central 1-mm circle representing the fovea, and inner and outer rings measuring 3
144 mm and 6 mm in diameter, respectively. The inner and outer rings are divided into four
145 quadrants each. The Cirrus OCT optic disc protocol generates images with 200 linear scans
146 enabling analysis of the RNFL of a 6-mm³ area around the optic nerve. For each scan series of
147 RNFL measurements, we assessed the average, superior, inferior, temporal, and nasal thickness.
148 Cirrus segmentation analysis for retinal layers also provides measurements of the GCL thickness,
149 evaluating six areas of the macular cube (superior, superonasal, inferonasal, inferior,
150 inferotemporal, and superotemporal sectors) and measurements of the average and minimum
151 GCL plus the inner plexiform layer (GCL + IPL) value of a set of 360 spokes, where each
152 average represents the mean number of the pixels along that spoke that lies within the
153 measurement annulus. The minimum is selected because the thinnest portion of the GCL + IPL
154 in the perifoveal region is considered to indicate damage to the ganglion cells.

155 All data analyses were performed using SPSS software version 20.0 (SPSS Inc., Chicago, IL).
156 Due to the parametric distribution of the data, differences between evaluations of PD patients
157 and healthy subjects were compared using Student's t-test. The linear correlation between
158 structural and functional parameters was determined using Pearson's correlation coefficient.
159 Values of $p < 0.05$ were considered to indicate statistical significance. Each eye was considered
160 separately, and one eye from each patient was randomly selected for analysis.

Results

Thirty-seven patients with PD and 37 healthy controls were included in the study. The mean age of the patients with PD was 69 years (range: 58–74 years) and the mean age of the healthy controls was 68 years (range: 60–76 years). Age ($p=0.361$), sex ($p=0.441$), and intraocular pressure ($p=0.720$) did not differ significantly between healthy controls and patients with PD. Mean time from diagnosis of PD was 13.2 years. The median Hoehn Yahr stage was 2.7, and the stage of PD based on the UPDRS was 25.06 (range: 7-39; Table 1).

Treatment was divided into three different categories: “Drugs that enhance dopamine levels” (carbidopa, levodopa and rasagiline), “dopaminergic drugs” (pramipexole, ropirinol, rotigotine), and “other”(amitriptiline, propranolol, clonazepam). “Drugs that enhance dopamine levels” was the most prescribed category (89% of patients) and combination therapy with levodopa and carbidopa was the most frequent treatment (44%). Sixty-four percent of treatments were categorized as “dopaminergic”, most of which were used in combination with drugs included in the previous category. A small percentage of patients (9%) were prescribed drugs with no dopaminergic effects.

PARAMETER	CONTROLS	PARKINSON DISEASE	p
Number of eyes (n)	37	37	-
Age, years, range	68 (60–76)	69 (58–74)	0.361
Men:Women (% of men)	24:13 (64.9)	23:14 (62.2)	0.441
Intraocular Pressure	15.58 (2.71)	15.12 (2.98)	0.720
Disease duration, years, mean (SD)	-	13.2 (5.77)	-
Hoehn Yahr, mean (SD)	-	2.7 (0.64)	-
UPDRS, mean (SD)	-	25.06 (8.24)	-

Functional parameters

PD patients had a lower BCVA at all three contrast levels of the ETDRS chart compared to the controls (0.18 ± 0.26 in patients vs -0.065 ± 0.9 in controls at 100%, $p=0.001$; 0.59 ± 0.21 vs 0.44 ± 0.13 at 2.50%, $p=0.01$; and 0.61 ± 0.23 vs 0.58 ± 0.16 at 1.25%, $p=0.009$). CSV was affected in patients at all four spatial frequencies of the CSV 1000E chart (3, 6, 12, and 18 cpd) when analyzed based on the number of correct localized gratings ($p=0.001$, <0.001 , <0.001 , and 0.004 respectively). The Pelli Robson results also revealed a significant reduction in CSV in PD patients (1.71 in patients vs 1.89 in controls, $p=0.02$). Color vision (L'Anthony test indexes) was also affected in PD. The results are shown in Table 2.

	HEALTHY CONTROLS		PARKINSON DISEASE PATIENTS		SIGNIFICANCE (P)
	Mean	SD	Mean	SD	
VA ETDRS 100	-0.06	0.096	0.18	0.26	0.001
VA ETDRS 2.5	0.44	0.13	0.59	0.22	0.010
VA ETDRS 1.25	0.58	0.16	0.62	0.23	0.009
Pelli Robson	1.89	0.11	1.71	0.17	0.002
CSV 1000 3 cpd	1.72	0.16	1.49	0.35	0.001*
CSV 1000 6 cpd	1.94	0.13	1.62	0.34	0.000*
CSV 1000 12 cpd	1.62	0.17	1.26	0.41	0.000*
CSV 1000 18 cpd	1.11	0.22	0.73	0.34	0.004*
Farnsworth AC CCI	1.11	0.22	0.73	0.34	0.851
Farnsworth C- index	1.10	0.20	1.24	0.42	0.093
Farnsworth CCI	1.07	0.12	1.14	0.24	0.110
Farnsworth Conf Angle	63.90	11.15	65.84	7.49	0.392
Farnsworth S-index	1.56	0.22	1.64	0.39	0.278
Farnsworth time	78.67	28.96	82.91	33.10	0.616
L'Anthony AC CCI	1.05	0.19	1.02	0.18	0.489
L'Anthony C-index	1.43	0.39	1.64	0.53	0.058
L'Anthony CCI	1.30	0.23	1.44	0.37	0.066
L'Anthony Conf Angle	62.31	14.74	71.91	9.25	0.002*
L'Anthony S-index	1.69	0.43	1.95	0.48	0.020
L'Anthony time	77.14	25.99	84.09	39.31	0.431

Structural parameters

OCT measurements indicated significant differences in superior macular sectors, in the outer inferior, outer temporal, and central macular thickness (results are shown in Table 2, Figure 1). The segmentation analysis revealed a significantly reduced GCL in PD patients in the superior (81.64±7.08 µm in patients vs 84.55±4.32 µm in controls; p=0.032) and superonasal sectors (81.04±7.23 µm vs 85.28±4.78 µm; p=0.029). The minimum GCL+IPL value was also reduced

(80.18±6.19 µm vs 82.45±3.60 µm; p=0.005). The RNFL was significantly reduced in the temporal quadrant in PD patients (Table 3).

	CONTROLS		PARKINSON DISEASE		
Structural parameters	Mean	SD	Mean	SD	P
<i>Macular measurements</i>					
Central macular thickness	254.75	17.903	248.96	17.765	0.028
Inner superior macular thickness	327.34	13.094	325.73	19.329	0.019
Inner nasal macular thickness	328.52	13.263	325.45	17.098	0.091
Inner inferior macular thickness	326.14	13.179	324.82	17.921	0.106
Inner temporal macular thickness	315.90	13.615	312.82	15.760	0.945
Outer superior macular thickness	284.76	9.418	279.44	17.981	0.008
Outer nasal macular thickness	302.41	12.167	299.18	17.064	0.074
Outer inferior macular thickness	277.79	10.755	273.76	16.798	0.045
Outer temporal macular thickness	271.52	10.992	266.23	18.987	0.013
<i>Ganglion cell layer thickness</i>					
Superior	84.55	4.323	81.61	7.087	0.032
Superonasal	85.28	4.780	81.04	7.234	0.029
Inferonasal	84.66	5.314	81.82	7.521	0.135
Inferior	84.34	5.052	81.91	6.252	0.389
Inferotemporal	85.79	4.003	83.73	4.860	0.233
Temporal	83.76	3.324	82.27	5.312	0.069
Average IPL+GCL	84.83	4.071	82.73	6.230	0.095
Min IPL+ GCL	82.45	3.601	80.18	6.194	0.005*
<i>RNFL thickness</i>					
Average	96.17	6.714	94.88	11.505	0.105
Superior	117.90	10.965	118.68	16.861	0.115
Nasal	73.59	12.724	72.40	15.182	0.345
Inferior	128.14	14.060	123.20	22.907	0.075
Temporal	64.97	8.218	61.48	10.553	0.027

Correlation between functional and structural parameters

CSV was the functional parameter most frequently associated with structural measurements in PD. The Pelli Robson CSV results correlated with GCL thickness in all sectors, although the

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

association was not strong ($r < 0.5$). The superonasal ($r=0.40$, $p=0.010$), inferonasal ($r=0.40$, $p=0.010$), inferior ($r=0.43$, $p=0.005$), superotemporal sector ($r=0.43$, $p=0.006$), and average GCL+IPL ($r=0.45$, $p=0.004$) values had the highest correlations. The Pelli Robson results also correlated with the thickness in different sectors of the RNFL (average, superior, and inferior sectors). Measurements with the CSV 1000E at different spatial frequencies correlated significantly with most GCL measurements. The superonasal ($r= 0.40$, $p= 0.013$) and superotemporal ($r= 0.44$, $p= 0.006$) thickness, average GCL +IPL thickness ($r= 0.40$, $p= 0.012$), and the minimum GCL + IPL ($r= 0.40$, $p=0.011$) at a spatial frequency of 6 cpd; and the superotemporal ($r= 0.41$, $p= 0.01$) thickness and the minimum GCL + IPL thickness ($r= 0.43$, $p=0.006$) at a spatial frequency of 18 cpd had the strongest correlations between CSV 1000E and GCL thickness. Spatial frequencies of 6 cpd and 18 cpd were strongly correlated with average macular thickness ($r= 0.79$, $p= 0.012$; $r= 0.77$, $p= 0.016$, respectively) and macular volume ($r= 0.78$, $p= 0.013$; $r= 0.78$, $p= 0.014$, respectively).

Color vision assessed by the L'Anthony test was also associated with the structural parameters: The C-index and CCI results were significantly correlated with all outer macular parameters and most of the GCL measurements (see Table 4). A significant association between color vision and the RNFL parameters was only found in isolated sectors. (see Table 4).

233

	L'Anthony color test					
	C-index	p	CCI	p	S-index	p
Macular thickness						
Central	-0.019	0.905	-0.059	0.716	-0.017	0.915
Inner superior	-0.146	0.369	-0.119	0.463	-0.167	0.302
Inner nasal	-0.055	0.735	-0.044	0.788	-0.040	0.807
Inner inferior	-0.073	0.654	-0.064	0.697	-0.074	0.649
Inner temporal	-0.049	0.764	-0.031	0.850	-0.126	0.439
Outer superior	-0.377	0.017	-0.380	0.015	-0.271	0.090
Outer nasal	-0.341	0.031	-0.323	0.042	-0.310	0.051
Outer inferior	-0.360	0.022	-0.353	0.025	-0.375	0.017
Outer temporal	-0.360	0.023	-0.361	0.022	-0.350	0.027
Macular average	-0.691	0.019	-0.657	0.028	-0.709	0.015
Macular volume	-0.686	0.020	-0.647	0.032	-0.709	0.015
Ganglion cell layer thickness						
Superior	-0.380	0.015	-0.369	0.019	-0.287	0.072
Superonasal	-0.383	0.015	-0.337	0.033	-0.350	0.027
Inferonasal	-0.338	0.033	-0.313	0.049	-0.268	0.094
Inferior	-0.341	0.031	-0.311	0.051	-0.282	0.078
Inferotemporal	-0.252	0.116	-0.263	0.101	-0.203	0.208
Temporal	-0.403	0.010	-0.437	0.005	-0.314	0.048
Average IPL+ GCL	-0.381	0.015	-0.358	0.023	-0.319	0.045
Minimum IPL+ GCL	-0.338	0.033	-0.326	0.040	-0.290	0.069

234

235 The strongest correlation was between the average macular thickness and macular volume and
 236 the L'Anthony CCI, C-index, and S-index results. No significant correlations were found
 237 between the Farnsworth's test parameters and structural measurements.

238 The VA ETDRS results correlated strongly with average macular thickness and macular volume
 239 (see Table 5, Figures 1 and 2). There were significant but mild associations between the GCL
 240 parameters and VA at 100% (superonasal, inferonasal, and average GCL + IPL thickness, $r=-$

1
2
3 241 0.38, p=0.016; r=-0.35, p=0.016; and r=0.35, p=0.029, respectively) and 2.50% (superonasal
4
5 242 sector, r=-0.36, p=0.023).

	Macular thickness	P value	Macular volume	P value
VA ETDRS 100	-0.765	0.006	-0.761	0.007
VA ETDRS 1.25	-0.718	0.013	-0.715	0.013
VA ETDRS 2.50	-0.738	0.010	-0.729	0.011

17 243
18
19
20 244 There was a significant correlation between Hoehn Yahr score and VA contrast level 2.50%
21
22 245 (r=0.48, p=0.040), and CS measured with CSV 1000 at a space frequency of 12 cpd (r=-0.59,
23
24 246 p=0.038). No correlations were detected between structural and disease severity parameters.

27
28 247 **Discussion**

29
30 248 In the present study, we evaluated the visual function parameters and assessed the association
31
32 249 between visual dysfunction and morphologic changes in the retina of 37 patients with PD.
33
34 250 Parameters corresponding to VA at different contrast levels, and all CSV tests results were
35
36 251 altered in PD patients in comparison with healthy subjects, prior to and after statistical correction
37
38 252 for multiple tests. Moreover, contrast sensitivity was the most affected parameter in our study
39
40 253 and correlated with most of the structural data. Color vision was measured with two different
41
42 254 tests, the Farnsworth and L'Anthony 15 D tests. These tests provide information for
43
44 255 differentiating subjects with severe loss of color vision from those with milder color defects or
45
46 256 normal color vision, and also can be used to evaluate acquired loss of color vision. In our study,
47
48 257 only the L'Anthony test results were significantly altered in PD patients. L'Anthony test is less
49
50 258 saturated than the Farnsworth color test, thus it is designed to detect more subtle color
51
52 259 deficiencies. Our patients performed worse than controls in both tests (higher C-index and S-

index, reaching ranges similar to protanomalies) although only the differences in L'Anthony S-index were statistically significant, indicating that our patients had a (subtle) protanomaly (S-index of 1.95).

Previous studies have indicated that PD patients lose foveal contrast sensitivity to patterns to which normal observers are most sensitive (i.e., requiring the least contrast for detection).[8,9] Ganglion cells in the retina show adaptation to visual contrast and pool visual inputs over their receptive fields through an array of parallel bipolar cells with smaller receptive fields.[21] The parvo- and magnocellular ganglion cells are located in the RGC layer and take two different pathways for the identification of color and contrast at different frequencies.[22] RGC loss (as observed using SD-OCT) was recently identified as the cause of visual impairment in patients suffering from another neurodegenerative process, multiple sclerosis.[23] Thus, a similar process could be the cause of the contrast and color deficiencies in patients with PD. In addition, in the mammalian retina, color vision and contrast sensitivity are modulated through D1 and D2 receptors. These dopaminergic receptors are differentially located in the retinal layers and a complete lack of activation leads to signal dispersion and alterations in color vision and contrast sensitivity.[2]

Alteration of the retinal layers in PD was first demonstrated in 2004.[24] Since then, various studies have demonstrated different results.[3-5,24-27] Previous studies performed by our team confirmed that both macular thickness and the RNFL were affected in patients with PD, especially in the inferior and temporal quadrants.[4,5, 28] Moreover, Garcia-Martin et al demonstrated that the inner retinal layers were most affected in these patients, and that the GCL thickness was inversely correlated with disease duration and PD severity, and was predictive of axonal damage in these patients.[29] The present study included a smaller number of patients,

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

283 which may have affected the significance of our results compared to previous studies. Despite
284 the small number of subjects in the present study, however, we detected significant reductions in
285 the macular, RNFL, and GCL thicknesses. A significant reduction in the temporal sectors of the
286 peripapillary RNFL thickness has been repeatedly observed by different groups [30, 31] and was
287 confirmed in the present study. Two recent studies, however, detected no differences in the
288 peripapillary RNFL thickness of PD patients compared to healthy controls using SD-OCT
289 [26,27] and one study only found significant differences in the nasal quadrant.[32] More studies
290 are required to clarify these contradictory observations.

291 In a previous study, we demonstrated that the retinal thickness corresponding to the
292 papillomacular bundle (as measured with the Axonal Analytics software for Spectralis OCT)
293 correlated ($r>0.70$) with some functional parameters (such as the mean defect and the pattern
294 standard deviation of the automated perimetry) in patients with PD.[33] The GCL was not
295 investigated at that time, however, and visual function parameters were reduced to perimetry and
296 color vision measured with the Ishihara color test. The current study evaluated not only the
297 RNFL but also the GCL thickness, and more visual function parameters were analyzed. The
298 GCL correlated most with the visual function parameters: GCL thickness was directly associated
299 with VA and CSV measured at all different spatial frequencies, and inversely correlated with the
300 color vision indexes. Thus, GCL thinning is linked to color deficiencies, contrast sensitivity loss,
301 and lower vision at different contrast levels in PD patients.

302 The degree of correlation is usually classified as low (<0.30), moderate ($0.30-0.70$), or strong
303 (>0.70). Our results revealed a low and moderate degree of correlation between most parameters,
304 consistent with findings in other neurodegenerative diseases.[34] Macular thickness and macular
305 volume, however, were strongly associated with functional parameters (VA, CS, and L'Anthony

CCI, C-index, and S-index). This strong association, to the best of our knowledge, has not been previously demonstrated in PD.

There are very few studies of the correlation between functional and structural parameters in PD patients. Adam et al [14] demonstrated a significant reduction in the inner retinal layer complex (RNFL + GCL + IPL) in PD patients, but no association with contrast sensitivity (measured with the Pelli Robson chart). A very recent study by Kaur et al [15] demonstrated a correlation between functional parameters and GCL thinning, consistent with our results. Kaur et al, however, found no significant alterations in VA or color vision in PD patients and the severity of the disease was not correlated with structural parameters, in contrast to other studies that demonstrate an association between macular and GCL thickness and disease duration and severity.[28,29] Although the severity of the disease in our sample (based on the Hoehn Yahr scale) was similar to that in Kaur's study, the duration of the disease in our study was higher than that in Kaur's patients (13 years vs 5 years), which may account for some of the differences in the results between the two studies. These discrepancies (and similarities) support the need for more studies on this topic. Our results, together with previously published studies,[15, 29] suggest that the GCL could be a reliable indicator of structural alterations in the retina of PD patients, demonstrating a significant correlation with functional tests in these patients. The results of the present study have important implications for clinical diagnosis and functional deficits in patients with PD, and highlight the importance of visual function tests in the evaluation of these patients.

In conclusion, visual dysfunction was significantly correlated with morphologic parameters in PD patients. PD patients present with a reduction in macular, RNFL, and GCL thickness, with changes in the GCL being most closely associated with visual dysfunction.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

329 This research received no specific grant from any funding agency in the public, commercial or not-for-
330 profit sectors.

331 **Competing interest:**

332 The authors disclose no conflict of interest.

333 **Data sharing:**

334 No additional data available.

335 **Contributorship:**

336 V. Polo: Research project: organization. Statistical analysis and Manuscript: Review and
337 critique.

338 M. Satue: Research project: Conception, design, organization and execution. Statistical analysis:
339 Review and critique. Manuscript: Writing of the first draft, review and critique.

340 MJ Rodrigo: Research project: organization and execution. Statistical analysis: Review and
341 critique. Manuscript: Writing of the first draft, review and critique.

342 S. Otin: Research project: organization and execution. Statistical analysis: Review and critique.
343 Manuscript: review and critique.

344 R. Alarcia: Research project: organization and execution. Statistical analysis: Review and
345 critique. Manuscript: review and critique.

346 MP. Bambo: Research project: execution. Statistical analysis: Review and critique. Manuscript:
347 review and critique.

348 MI. Fuertes: Research project: execution. Statistical analysis: Review and critique. Manuscript:
349 review and critique.

350 JM. Larrosa: Research project: execution. Statistical analysis: Review and critique. Manuscript:
351 review and critique.

352 LE. Pablo: Research project: execution. Statistical analysis: Review and critique. Manuscript:

353 review and critique.

354 E. Garcia-Martin: Research project: Conception, design, organization and execution. Statistical
355 analysis: Design, execution, review and critique. Manuscript: Writing of the first draft, review
356 and critique.

357

358

359

360

361

362

References

1. Bodis-Wollner I. Retinopathy in Parkinson disease. *J Neural Transm* 2009;116:1493-501.

2. Hajee ME, March WF, Lazzaro DR et al. Inner retinal layer thinning in Parkinson's disease. *Arch Ophthalmol* 2009;127:737-41.

3. Cubo E, Tedejo RP, Rodriguez Mendez V. Retina thickness in Parkinson's disease and essential tremor. *Mov Disord* 2010;25:2461-77.

4. Satue M, Garcia-Martin E, Fuertes I et al. Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson's disease patients. *Eye (Lond)* 2013;27:507-14.

5. Garcia-Martin E, Satue M, Fuertes I et al. Ability and reproducibility of Fourier domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson's disease. *Ophthalmology* 2012;119:2161-7.

6. Fisher JB, Jacobs DA, Markowitz CE et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. *Ophthalmology* 2006;113:324.

7. Parisi V, Manni G, Spadaro M et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. *Invest Ophthalmol Vis Sci* 1999;40:2520-7.

8. Bodis-Wollner I. Visual acuity and contrast sensitivity in patients with cerebral lesions. *Science* 1972;178:769-71.

9. Bodis-Wollner I, Diamond S. The measurement of spatial contrast sensitivity in cases of blurred vision associated with cerebral lesions. *Brain* 1976;99:695-710.

10. Price MJ, Feldman RG, Adelberg D et al. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. *Neurology* 1992;42:887-90.

11. Oh YS, Kim JS, Chung SW et al. Color vision in Parkinson's disease and essential tremor. European Journal of Neurology 2011;18: 577-83.
12. Hipp G, Diederichs NJ, Pieria V et al. Primary vision and facial emotion recognition in early Parkinson's disease. Journal of the Neurological Sciences 2014;338 :178-82.
13. Archibald NK, Clarke MP, Mosimann UP et al. Retinal thickness in Parkinson's disease. Parkinsonism Relat Disord 2011; 17(6):431-6.
14. Adam CR1, Shrier E, Ding Y et al. Correlation of inner retinal thickness evaluated by spectral-domain optical coherence tomography and contrast sensitivity in Parkinson disease. J Neuroophthalmol. 2013;33(2):137-42.
15. Kaur M, Saxena R, Singh D et al. Correlation Between Structural and Functional Retinal Changes in Parkinson Disease. J Neuroophthalmol 2015 [Epub ahead of print]
16. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-9.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
18. Ramaker C, Marinus J, Stiggelbout AM, et al. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord 2002;17(5):867-76.
19. Vingrys AJ, King-Smith PE. A quantitative scoring technique for panel tests of color vision. Invest Ophthalmol Vis Sci 1988;29(1):50-63.
20. Bowman AJ. A method for quantitative scoring of the Farnsworth panel D15. Acta Ophthalmologica 1982;60:907-16.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21. Kim, KJ, Rieke, F. Temporal contrast adaptation in the input and output signals of
salamander retinal ganglion cells. *J. Neurosci* 2001;21:287-99.

22. Laycock R, Crewther SG, Crewther DP. A role for the ‘magnocellular advantage’ in visual
impairments in neurodevelopmental and psychiatric disorders. *Neurosci Biobehav Rev.*
2007;31:363-76.

23. Lampert EJ, Andorra M, Torres-Torres R, et al. Color vision impairment in multiple sclerosis
points to retinal ganglion cell damage. *J Neurol.* 2015 [Epub ahead of print]

24. Inzelberg R, Ramirez JA, Nisipeanu P et al. Retinal nerve fiber layer thinning in Parkinson’s
disease. *Vision Res* 2004;44:2793-7.

25. Altıntaş O, Işeri P, Ozkan B et al. Correlation between retinal morphological and functional
findings and clinical severity in Parkinson’s disease. *Doc Ophthalmol* 2008;116:137-46.

26. Bittersohl D, Stemplewitz B, Keserü M et al. Detection of retinal changes in idiopathic
Parkinson's disease using high-resolution optical coherence tomography and Heidelberg retina
tomography. *Acta Ophthalmol.* 2015;93(7):e578-84.

27. Chorostecki J, Seraji-Bozorgzad N, Shah A et al. Characterization of retinal architecture in
Parkinson's disease. *J Neurol Sci.* 2015;355(1-2):44-8.

28. Satue M, Seral M, Otin S et al. Retinal thinning and correlation with functional disability in
patients with Parkinson's disease. *Br J Ophthalmol* 2014;98(3):350-5.

29. Garcia-Martin E, Larrosa JM, Polo V et al. Distribution of retinal layer atrophy in patients
with Parkinson disease and association with disease severity and duration. *Am J Ophthalmol*
2014;157(2):470-8.

30. Sari ES, Koc R, Yazici A, Sahin G, Ermis SS. Ganglion cell-inner plexiform layer thickness in patients with Parkinson disease and association with disease severity and duration. *J Neuroophthalmol*. 2015;35(2):117-21.
31. La Morgia C, Barboni P, Rizzo G et al. Loss of temporal retinal nerve fibers in Parkinson disease: a mitochondrial pattern? *Eur J Neurol*. 2013;20(1):198-201
32. Bayhan HA, Aslan Bayhan S, Tanık N, Gürdal C. The association of spectral-domain optical coherence tomography determined ganglion cell complex parameters and disease severity in Parkinson's disease. *Curr Eye Res*. 2014;39(11):1117-22.
33. Satue M, Bambo M, Garcia-Martin E, et al. Correlation between function and structure of retinal nerve fiber layer in Parkinson disease. *Acta Ophthalmologica*. 2012;90:0.
34. Garcia-Martin E, Rodriguez-Mena D, Herrero R, et al. Neuro-ophthalmologic evaluation, quality of life and functional disability in MS patients. *Neurology* 2013;81:1-8.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends

Figure 1 Correlation between the average macular thickness and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson’s disease.

Figure 2: Correlation between macular volume and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson’s disease.

Table 1: Epidemiologic and disease characteristics of patients with PD and healthy subjects, and statistical significance (P). Abbreviations: SD, standard deviation; UPDRS, Unified Parkinson Disease Rating Scale.

Table 2: Mean and standard deviation (SD) of visual functional parameters in healthy controls and subjects with Parkinson disease. Results in bold letters indicate statistical significance ($p<0.05$). The asterisk indicates those values with statistical significance after Bonferroni correction for multiple tests ($p<0.0125$ for CSV 1000E measurements; $p<0.0083$ for Farnsworth and L’Anthony tests). Abbreviations: VA, visual acuity; ETDRS, early treatment diabetic retinopathy study; cpd, cycles per degree; AC CCI, age corrected color confusion index; CCI, color confusion index; C-index, confusion index; Conf Angle, confusion angle; S-index, scatter index; PD, Parkinson disease.

Table 3: Mean and standard deviation (SD) of structural parameters (retinal nerve fiber layer, ganglion cell layer and macular thicknesses) obtained with the Cirrus HD optical coherence

tomography device in healthy controls and subjects with Parkinson disease. Bold letters indicate statistical significance ($p < 0.05$). The asterisk indicates those values with statistical significance after Bonferroni correction for multiple tests ($p < 0.0055$ for macular measurements; $p < 0.0062$ for ganglion cell measurements and $p < 0.01$ for RNFL measurements). Abbreviations: IPL, inner plexiform layer; GCL, ganglion cell layer; RNFL, retinal nerve fiber layer; HD, high definition.

Table 4: Correlation between macular and ganglion cell layer structural measurements and color vision evaluated with L'Anthony color test in patients with Parkinson disease. Data in bold type correspond to statistically significant correlations (p value < 0.05). Abbreviations: GCL, ganglion cell layer; IPL, inner plexiform layer; C-index, Confusion index; CCI, color confusion index; S-index, Scatter index.

Table 5: Correlation between visual acuity measured with ETDRS chart at different levels of contrast (in %) and macular structural measurements (thickness and volume) in patients with Parkinson disease. Correlation data in bold type are statistically significant (p value < 0.05). Abbreviations: VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.




Figure 1: Correlation between the average macular thickness and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson’s disease. 118x100mm (300 x 300 DPI)




Figure 2: Correlation between macular volume and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson's disease.
119x102mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract Check. This included in the abstract, methods, line 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Check. This is included in the abstract. Methods, from line 2 to results section line 9
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Check. This is included in the introduction. Paragraph 2.
Objectives	3	State specific objectives, including any prespecified hypotheses Check. This is included in the introduction. Paragraph 3.
Methods		
Study design	4	Present key elements of study design early in the paper Check. This is included in Methods, paragraph 1-3.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Check. This is included in Methods, paragraph 1-3.
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Check. This is included in Methods, paragraph 2
		(b) For matched studies, give matching criteria and the number of controls per case Check. This is included in Methods, paragraph 1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Check. Outcomes and variables are explained in Methods, paragraphs 4-8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Check. Details of measurements are included in paragraphs 4-8.
Bias	9	Describe any efforts to address potential sources of bias Check. This is included in paragraph 8, line 3-4.
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Check. Quantitative variables are explained in Methods, paragraphs 4-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding. Check. This is included in methods, paragraph 9
		(b) Describe any methods used to examine subgroups and interactions. Not applicable.
		(c) Explain how missing data were addressed Not applicable
		(d) If applicable, explain how matching of cases and controls was addressed Not applicable
		(e) Describe any sensitivity analyses Not applicable

Results

Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</p> <hr/> <p>(b) Give reasons for non-participation at each stage</p> <hr/> <p>(c) Consider use of a flow diagram</p> <p>This is a cross sectional study. Inclusion criteria were explained in methods. All eligible subjects were included in the study (37) as already explained, all completed the evaluation.</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Check. This is included in Results, paragraph 1-2 and table 1.</p> <hr/> <p>(b) Indicate number of participants with missing data for each variable of interest</p> <p>Not applicable.</p>
Outcome data	15*	<p>Report numbers in each exposure category, or summary measures of exposure</p> <p>Check. Numbers and results of each variable are included in results.</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>Check. Main results include statistical results prior and post multiple comparisons adjustment.</p> <hr/> <p>(b) Report category boundaries when continuous variables were categorized Check. Category of correlation is explained in discussion, paragraph 5</p> <hr/> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Not applicable</p>

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Not applicable
Discussion		
Key results	18	Summarise key results with reference to study objectives Check. This is included in results, paragraph 1.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Check, this is mentioned in paragraph 3 and 6.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Check. This is included and discussed along the discussion section.
Generalisability	21	Discuss the generalisability (external validity) of the study results Check. This is included and discussed along the discussion section
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Check. Not applicable.

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Visual dysfunction and its correlation with retinal changes in patients with Parkinson disease

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2015-009658.R2
Article Type:	Research
Date Submitted by the Author:	26-Jan-2016
Complete List of Authors:	Polo, Vicente; Miguel Servet University Hospital, Ophthalmology Satue, Maria; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Rodrigo, Maria Jesus; Miguel Servet University Hospital, Ophthalmology Otin, Sofia; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Alarcia, Raquel; Miguel Servet University Hospital, Neurology Bambo, Maria; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Fuertes, Isabel; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Larrosa, Jose; Hospital Universitario Miguel Servet, Ophthalmology; Institute for Sanitary Research of Aragon (IISA), Pablo, Luis; Miguel servet University Hospital, Ophthalmology; Institute for Sanitary Research of Aragon (IISA), Garcia-Martin, Elena; Miguel Servet University Hospital, Ophthalmology; Institute for Sanitary Research of Aragon (IISA),
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Ophthalmology, Neurology
Keywords:	Neuro-ophthalmology < NEUROLOGY, Parkinson-s disease < NEUROLOGY, Neuro-ophthalmology < OPHTHALMOLOGY

SCHOLARONE™
Manuscripts

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Visual dysfunction and its correlation with retinal changes in patients with Parkinson disease: an observational prospective study

AUTHORS:

Polo V^{1,2}, Satue M^{1,2}, Rodrigo MJ¹, Otin S^{1,2}, Alarcia R^{1,3}, Bambo MP^{1,2}, Fuertes MI^{1,2}, Larrosa JM^{1,2}, Pablo LE^{1,2}, Garcia-Martin E^{1,2}.

AFFILIATIONS:

- ¹ IIS Aragon. Insitute for Health Sciencies of Aragon, Zaragoza, Spain.
- ² Ophthalmology Department, Miguel Servet University Hospital, Zaragoza, Spain.
- ³ Neurology Department, Miguel Servet University Hospital, Zaragoza, Spain.

CORRESPONDENCE:

Maria Satue
C/ Padre Arrupe. Consultas Externas de Oftalmología 50009-Zaragoza (Spain)
Email: mariasatue@gmail.com Telephone: 0034.976.76.55.58

RUNNING TITLE: OCT and visual dysfunction in Parkinson disease
STUDY DESIGN AND SETTING: An observational prospective study, carried out at Miguel Servet University Hospital, in Zaragoza, Spain.
KEY WORDS: Parkinson disease, visual function, contrast sensitivity, ganglion cell layer.
WORD COUNT: 2500 words.
All subjects provided detailed consent to participate in this study, which was conducted in accordance with the guidelines established by the Ethics Committee of the Miguel Servet Hospital and based on the principles of the Declaration of Helsinki.
This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

26 The authors disclose no conflict of interest.

27

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

28 SUBTITLE: Visual acuity, contrast sensitivity vision and color vision are affected in Parkinson
29 disease. Visual dysfunction in these patients correlates with structural changes in the retina
30 measured with Spectral domain OCT.

For peer review only

Abstract

Objectives: To evaluate visual dysfunction and its correlation with structural changes in the retina in patients with Parkinson disease (PD).

Methods: Patients with PD (n=37) and controls (n=37) were included in an observational cross-sectional study and underwent visual acuity (VA), color vision (using the Farnsworth and L'Anthony desaturated D15 color tests), and contrast sensitivity vision (CSV; using the Pelli Robson chart and CSV 1000E test) evaluation to measure visual dysfunction. Structural measurements of the retinal nerve fiber layer (RNFL), and macular and ganglion cell layer (GCL) thicknesses were obtained using spectral domain optical coherence tomography (SD-OCT). Comparison of obtained data and correlation analysis between functional and structural results were performed.

Results: VA (in all different contrast levels) and all CSV spatial frequencies were significantly worse in PD patients than in controls ($P < 0.05$). Color vision was significantly affected ($p < 0.05$) based on the L'Anthony color test. Macular thinning was detected in the central, outer (inferior and temporal), and superior (inner and outer) sectors ($p < 0.05$), and the RNFL had significant thinning in the temporal quadrant ($p < 0.05$). Significant GCL loss was observed in the superior and superonasal sectors and the minimum GCL + inner plexiform layer ($p < 0.05$). CSV was the functional parameter most strongly correlated with structural measurements in PD. Color vision was associated with most GCL measurements. Macular thickness was strongly correlated with macular volume and functional parameters ($r > 0.70$, $p < 0.05$).

Conclusions: Patients with PD had visual dysfunction that correlated with structural changes evaluated by SD-OCT. Macular and GCL measurements may be reliable indicators of visual impairment in PD patients.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Strengths and limitations of this study:

The strengths of this study should be resumed by the following bullet points:

- We detected alteration in VA (at different contrast levels), CSV and CV in PD patients. CSV correlated with most of the structural data.
- We detected significant reductions in the macular, RNFL, and GCL thicknesses. The GCL correlated most with the visual function parameters.
- There are only 2 other published articles evaluating the association between visual dysfunction and morphologic parameters. Results provided by these previous studies differ from our results, possibly due to different measurement methods and sample size.
- CV in our study was assessed by L'Anthony and Farnsworth D15 color tests, which may provide more specific information about color deficiencies. These tests are not commonly used to evaluate color deficiencies in PD patients.
- Macular thickness and macular volume were strongly associated with functional parameters. This is the first time such a strong correlation is reported ($r>0.70$).

74

75 **Introduction**

76 Foveal vision alterations are associated with Parkinson disease (PD), and seem to be caused by
77 dysfunction of the intraretinal dopaminergic circuitry and final retinal output to the brain.[1]
78 Recent studies demonstrated retinal thinning in PD patients compared with healthy subjects.[2-5]
79 Several studies report a correlation between functional disability and axonal loss observed in the
80 optic nerve in multiple sclerosis, another neurodegenerative process.[6,7] PD patients are also
81 reported to have decreased contrast sensitivity and color vision, and altered visual evoked
82 potentials.[1,8-13] To our knowledge, however, very few studies have assessed visual
83 dysfunction in PD and its correlation with morphologic parameters.[14,15]

84 In the present study, we evaluated visual acuity (VA) using an Early Treatment Diabetic
85 Retinopathy Study (ETDRS) chart, contrast sensitivity vision (CSV) using the CSV-1000E test
86 and Pelli-Robson chart, and color vision using the Farnsworth and L'Anthony tests in PD
87 patients and healthy controls to examine the association between visual dysfunction and
88 morphologic parameters.

89

90 **Material and methods**

91 Thirty-seven eyes of 37 patients with definite PD and 37 eyes of 37 age- and sex-matched
92 healthy individuals were recruited for the study. The study was performed at Miguel Servet
93 University Hospital in Zaragoza, Spain. All procedures adhered to the tenets of the Declaration
94 of Helsinki, and all participants provided informed consent to participate in the study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

95 The diagnosis of PD was based on standard clinical and neuroimaging criteria.[16] Information
96 about disease severity was assessed using the Hoehn Yahr scale [17] and the Unified Parkinson
97 Disease Rating Scale part III score (UPDRS III) [18]. Disease duration and treatment were
98 recorded. Exclusion criteria were the presence of significant refractive errors (>5 diopters of
99 spherical equivalent refraction or 3 diopters of astigmatism); intraocular pressure ≥ 21 mmHg;
100 media opacifications; concomitant ocular diseases, including history of glaucoma or retinal
101 pathology; and systemic conditions that could affect the visual system. The healthy controls had
102 no history and no evidence of ocular or neurologic disease of any nature; their best-corrected
103 visual acuity (BCVA) was >20/30 based on the Snellen scale.

104 All subjects underwent a complete neuro-ophthalmic evaluation that included pupillary, anterior
105 segment, and funduscopy examination. Visual function was assessed by evaluating BCVA using
106 an ETDRS chart, CSV using the CVS-1000E test and Pelli-Robson chart, and color vision using
107 the Farnsworth desaturated D15 and L'Anthony desaturated D15 tests. Structural analysis of the
108 retina was performed using Spectral domain (SD) optical coherence tomography (OCT) with the
109 Cirrus High definition (HD) OCT (Carl Zeiss Meditec Inc, Dublin, CA), which included three
110 different protocols: macular protocol (for macular thickness analysis), RNFL protocol, and
111 ganglion cell protocol (for individual analysis of this layer).

112 LogMAR visual acuity (VA) was evaluated at three different contrast levels: 100% (HCVA,
113 using ETDRS chart), 2.50%, and 1.25% (LCVA, using Low-Contrast Sloan Letter Charts -
114 Precision Vision, LaSalle, IL-), The percentage indicating the level of contrast, i.e., 100%
115 representing black letters over white background and 1.25% light grey letters over white
116 background. All measurements were obtained under monocular vision and controlled lighting
117 conditions with best correction.

Contrast sensitivity provides more complete information about visual function than visual acuity tests. CSV was evaluated in our patients using the Pelli-Robson chart and the CVS-1000E test. The Pelli-Robson chart comprises horizontal lines of capital letters organized into groups of three (triplets) with two triplets per line. Within each triplet, all letters have the same contrast. The contrast decreases from one triplet to the next, even within each line. All patients were evaluated under both monocular and binocular vision at a distance of 1 meter from the chart and under controlled photopic conditions (85 cd/m^2). The score corresponding to the last triplet of letters seen by the patient was recorded.

The CSV-1000E instrument is used worldwide for standardized CSV and glare testing. All patients were evaluated at a distance of 2.5 meters from the chart under monocular vision at 4 different spatial frequencies (3, 6, 12, and 18 cycles per degree [cpd]). The chart comprises four rows with 17 circular patches each. The patches present a grating that decreases in contrast moving from left to right across the row. The patient indicates whether the grating appears in the top patch or the bottom patch for each column. Each contrast value for each spatial frequency was transformed into a logarithmic scale according to standardized values.

Color vision was assessed using the Color Vision Recorder (CVR) program. CVR software analyzes chromatic discrimination by classification of colors. The program includes the classic test of Farnsworth 100-hue (FM-100), Farnsworth - Munsell D15, and L'Anthony D15. All patients in the study were evaluated using the Farnsworth - Munsell D15 and L'Anthony D15 protocols and different output parameters such as the Confusion Index (C-index), the Color Confusion Index (CCI), the Confusion angle (Conf Ang), and the Scatter Index (S-index) were recorded.[19,20] The tests were performed under monocular vision.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

140 Structural measurements of the retina were obtained using the Cirrus OCT device. The same
141 experienced operator performed all scans and did not apply manual correction to the OCT
142 output. We used an internal fixation target because it provides the highest reproducibility and
143 rejected poor quality scans prior to data analysis. The Cirrus OCT macular cube 512 x 128
144 protocol provides a macular volume measure and retinal thickness values for nine areas. These
145 areas include a central 1-mm circle representing the fovea, and inner and outer rings measuring 3
146 mm and 6 mm in diameter, respectively. The inner and outer rings are divided into four
147 quadrants each. The Cirrus OCT optic disc protocol generates images with 200 linear scans
148 enabling analysis of the RNFL of a 6-mm³ area around the optic nerve. For each scan series of
149 RNFL measurements, we assessed the average, superior, inferior, temporal, and nasal thickness.
150 Cirrus segmentation analysis for retinal layers also provides measurements of the GCL thickness,
151 evaluating six areas of the macular cube (superior, superonasal, inferonasal, inferior,
152 inferotemporal, and superotemporal sectors) and measurements of the average and minimum
153 GCL plus the inner plexiform layer (GCL + IPL) value of a set of 360 spokes, where each
154 average represents the mean number of the pixels along that spoke that lies within the
155 measurement annulus. The minimum is selected because the thinnest portion of the GCL + IPL
156 in the perifoveal region is considered to indicate damage to the ganglion cells.

157 All data analyses were performed using SPSS software version 20.0 (SPSS Inc., Chicago, IL).
158 Due to the parametric distribution of the data, differences between evaluations of PD patients
159 and healthy subjects were compared using Student's t-test. To avoid a high false positive rate,
160 the Bonferroni correction for multiple comparisons was calculated. The level of significance for
161 each variable was established based on Bonferroni calculations.

The linear correlation between structural and functional parameters was determined using Pearson's correlation coefficient. Values of $p < 0.05$ were considered to indicate a significant correlation. Each eye was considered separately, and one eye from each patient was randomly selected for analysis.

Results

Thirty-seven patients with PD and 37 healthy controls were included in the study. The mean age of the patients with PD was 69 years (range: 58–74 years) and the mean age of the healthy controls was 68 years (range: 60–76 years). Age ($p=0.361$), sex ($p=0.441$), and intraocular pressure ($p=0.720$) did not differ significantly between healthy controls and patients with PD. Mean time from diagnosis of PD was 13.2 years. The median Hoehn Yahr stage was 2.7, and the stage of PD based on the UPDRS III was 25.06 (range: 7–39; Table 1).

Treatment was divided into three different categories: “Drugs that enhance dopamine levels” (carbidopa, levodopa and rasagiline), “dopaminergic drugs” (pramipexole, ropiridinol, rotigotine), and “other”(amitriptyline, propranolol, clonazepam). “Drugs that enhance dopamine levels” was the most prescribed category (89% of patients) and combination therapy with levodopa and carbidopa was the most frequent treatment (44%). Sixty-four percent of treatments were categorized as “dopaminergic”, most of which were used in combination with drugs included in the previous category. A small percentage of patients (9%) were prescribed drugs with no dopaminergic effects.

PARAMETER	CONTROLS	PARKINSON DISEASE	p
Number of eyes (n)	37	37	-
Age, years, range	68 (60–76)	69 (58–74)	0.361
Men:Women (% of men)	24:13 (64.9)	23:14 (62.2)	0.441
Intraocular Pressure	15.58 (2.71)	15.12 (2.98)	0.720
Disease duration, years, mean (SD)	-	13.2 (5.77)	-
Hoehn Yahr, mean (SD)	-	2.7 (0.64)	-
UPDRS III, mean (SD)	-	25.06 (8.24)	-

Functional parameters

PD patients had a lower BCVA at all three contrast levels of the ETDRS chart compared to the controls (0.18 ± 0.26 in patients vs -0.065 ± 0.9 in controls at 100%, $p=0.001$; 0.59 ± 0.21 vs 0.44 ± 0.13 at 2.50%, $p=0.010$; and 0.61 ± 0.23 vs 0.58 ± 0.16 at 1.25%, $p=0.009$). CSV was affected in patients at all four spatial frequencies of the CSV 1000E chart (3, 6, 12, and 18 cpd) when analyzed based on the number of correct localized gratings ($p=0.001$, <0.001 , <0.001 , and 0.004 respectively). The Pelli Robson results also revealed a significant reduction in CSV in PD patients (1.71 in patients vs 1.89 in controls, $p=0.02$). Color vision (Conf Angle in L'Anthony test) was also affected in PD. The results are shown in Table 2.

	HEALTHY CONTROLS		PARKINSON DISEASE PATIENTS		SIGNIFICANCE (P)
	Mean	SD	Mean	SD	
VA ETDRS 100	-0.06	0.096	0.18	0.26	0.001*
VA ETDRS 2.5	0.44	0.13	0.59	0.22	0.010*
VA ETDRS 1.25	0.58	0.16	0.62	0.23	0.009*
Pelli Robson	1.89	0.11	1.71	0.17	0.002*
CSV 1000 3 cpd	1.72	0.16	1.49	0.35	0.001*
CSV 1000 6 cpd	1.94	0.13	1.62	0.34	<0.001*
CSV 1000 12 cpd	1.62	0.17	1.26	0.41	<0.001*
CSV 1000 18 cpd	1.11	0.22	0.73	0.34	0.004*
Farnsworth AC CCI	1.11	0.22	0.73	0.34	0.851
Farnsworth C- index	1.10	0.20	1.24	0.42	0.093
Farnsworth CCI	1.07	0.12	1.14	0.24	0.110
Farnsworth Conf Angle	63.90	11.15	65.84	7.49	0.392
Farnsworth S-index	1.56	0.22	1.64	0.39	0.278
Farnsworth time	78.67	28.96	82.91	33.10	0.616
L'Anthony AC CCI	1.05	0.19	1.02	0.18	0.489
L'Anthony C-index	1.43	0.39	1.64	0.53	0.058
L'Anthony CCI	1.30	0.23	1.44	0.37	0.066
L'Anthony Conf Angle	62.31	14.74	71.91	9.25	0.002*
L'Anthony S-index	1.69	0.43	1.95	0.48	0.020
L'Anthony time	77.14	25.99	84.09	39.31	0.431

198

199 *Structural parameters*

200 Based on Bonferroni corrections, OCT measurements indicated a significant difference in the
 201 minimum GCL+IPL value ($80.18 \pm 6.19 \mu\text{m}$ vs $82.45 \pm 3.60 \mu\text{m}$; $p=0.005$). However, we observed
 202 a clear tendency towards a reduction in superior macular sectors, in the outer inferior, outer
 203 temporal, and central macular thickness in PD patients compared to controls: the p value for
 204 these variables was <0.05 but did not meet Bonferroni significance (results are shown in Table
 205 2). The segmentation analysis revealed a tendency towards reduced GCL in PD patients in the
 206 superior ($81.64 \pm 7.08 \mu\text{m}$ in patients vs $84.55 \pm 4.32 \mu\text{m}$ in controls; $p=0.032$) and superonasal
 207 sectors ($81.04 \pm 7.23 \mu\text{m}$ vs $85.28 \pm 4.78 \mu\text{m}$; $p=0.029$); and the RNFL was reduced in the

temporal quadrant in PD patients (Table 3). These parameters however, did not meet the level of significance established by Bonferroni correction.

Structural parameters	CONTROLS		PARKINSON DISEASE		P
	Mean	SD	Mean	SD	
<i>Macular measurements</i>					
Central macular thickness	254.75	17.903	248.96	17.765	0.028
Inner superior macular thickness	327.34	13.094	325.73	19.329	0.019
Inner nasal macular thickness	328.52	13.263	325.45	17.098	0.091
Inner inferior macular thickness	326.14	13.179	324.82	17.921	0.106
Inner temporal macular thickness	315.90	13.615	312.82	15.760	0.945
Outer superior macular thickness	284.76	9.418	279.44	17.981	0.008
Outer nasal macular thickness	302.41	12.167	299.18	17.064	0.074
Outer inferior macular thickness	277.79	10.755	273.76	16.798	0.045
Outer temporal macular thickness	271.52	10.992	266.23	18.987	0.013
<i>Ganglion cell layer thickness</i>					
Superior	84.55	4.323	81.61	7.087	0.032
Superonasal	85.28	4.780	81.04	7.234	0.029
Inferonasal	84.66	5.314	81.82	7.521	0.135
Inferior	84.34	5.052	81.91	6.252	0.389
Inferotemporal	85.79	4.003	83.73	4.860	0.233
Temporal	83.76	3.324	82.27	5.312	0.069
Average IPL+GCL	84.83	4.071	82.73	6.230	0.095
Min IPL+ GCL	82.45	3.601	80.18	6.194	0.005*
<i>RNFL thickness</i>					
Average	96.17	6.714	94.88	11.505	0.105
Superior	117.90	10.965	118.68	16.861	0.115
Nasal	73.59	12.724	72.40	15.182	0.345
Inferior	128.14	14.060	123.20	22.907	0.075
Temporal	64.97	8.218	61.48	10.553	0.027

Correlation between functional and structural parameters

CSV was the functional parameter most frequently associated with structural measurements in PD. The Pelli Robson CSV results correlated with GCL thickness in all sectors, although the

association was not strong ($r < 0.5$). The superonasal ($r=0.40$, $p=0.010$), inferonasal ($r=0.40$, $p=0.010$), inferior ($r=0.43$, $p=0.005$), superotemporal sector ($r=0.43$, $p=0.006$), and average GCL+IPL ($r=0.45$, $p=0.004$) values had the highest correlations. The Pelli Robson results also correlated with the thickness in different sectors of the RNFL (average, superior, and inferior sectors). Measurements with the CSV 1000E at different spatial frequencies correlated significantly with most GCL measurements. The superonasal ($r=0.40$, $p=0.013$) and superotemporal ($r=0.44$, $p=0.006$) thickness, average GCL +IPL thickness ($r=0.40$, $p=0.012$), and the minimum GCL + IPL ($r=0.40$, $p=0.011$) at a spatial frequency of 6 cpd; and the superotemporal ($r=0.41$, $p=0.01$) thickness and the minimum GCL + IPL thickness ($r=0.43$, $p=0.006$) at a spatial frequency of 18 cpd had the strongest correlations between CSV 1000E and GCL thickness. Spatial frequencies of 6 cpd and 18 cpd were strongly correlated with average macular thickness ($r=0.79$, $p=0.012$; $r=0.77$, $p=0.016$, respectively) and macular volume ($r=0.78$, $p=0.013$; $r=0.78$, $p=0.014$, respectively, Figure 1).

Color vision assessed by the L'Anthony test was also associated with the structural parameters: The C-index and CCI results were significantly correlated with all outer macular parameters and most of the GCL measurements (see Table 4). A significant association between color vision and the RNFL parameters was only found in isolated sectors. (see Table 4).

	L'Anthony color test					
	C-index	p	CCI	p	S-index	p
Macular thickness						
Central	-0.019	0.905	-0.059	0.716	-0.017	0.915
Inner superior	-0.146	0.369	-0.119	0.463	-0.167	0.302
Inner nasal	-0.055	0.735	-0.044	0.788	-0.040	0.807
Inner inferior	-0.073	0.654	-0.064	0.697	-0.074	0.649
Inner temporal	-0.049	0.764	-0.031	0.850	-0.126	0.439
Outer superior	-0.377	0.017	-0.380	0.015	-0.271	0.090
Outer nasal	-0.341	0.031	-0.323	0.042	-0.310	0.051
Outer inferior	-0.360	0.022	-0.353	0.025	-0.375	0.017
Outer temporal	-0.360	0.023	-0.361	0.022	-0.350	0.027
Macular average	-0.691	0.019	-0.657	0.028	-0.709	0.015
Macular volume	-0.686	0.020	-0.647	0.032	-0.709	0.015
Ganglion cell layer thickness						
Superior	-0.380	0.015	-0.369	0.019	-0.287	0.072
Superonasal	-0.383	0.015	-0.337	0.033	-0.350	0.027
Inferonasal	-0.338	0.033	-0.313	0.049	-0.268	0.094
Inferior	-0.341	0.031	-0.311	0.051	-0.282	0.078
Inferotemporal	-0.252	0.116	-0.263	0.101	-0.203	0.208
Temporal	-0.403	0.010	-0.437	0.005	-0.314	0.048
Average IPL+ GCL	-0.381	0.015	-0.358	0.023	-0.319	0.045
Minimum IPL+ GCL	-0.338	0.033	-0.326	0.040	-0.290	0.069

The strongest correlation was between the average macular thickness and macular volume and the L'Anthony CCI, C-index, and S-index results. No significant correlations were found between the Farnsworth's test parameters and structural measurements.

The VA ETDRS results correlated strongly with average macular thickness and macular volume (see Table 5, Figures 2 and 3). There were significant but mild associations between the GCL parameters and VA at 100% (superonasal, inferonasal, and average GCL + IPL thickness, $r=-$

0.38, $p=0.016$; $r=-0.35$, $p=0.016$; and $r=0.35$, $p=0.029$, respectively) and 2.50% (superonasal sector, $r=-0.36$, $p=0.023$).

	Macular thickness	P value	Macular volume	P value
VA ETDRS 100	-0.765	0.006	-0.761	0.007
VA ETDRS 1.25	-0.718	0.013	-0.715	0.013
VA ETDRS 2.50	-0.738	0.010	-0.729	0.011

There was a significant correlation between Hoehn Yahr score and VA contrast level 2.50% ($r=0.48$, $p=0.040$), and CS measured with CSV 1000 at a space frequency of 12 cpd ($r=-0.59$, $p=0.038$). No correlations were detected between structural and disease severity parameters.

Discussion

In the present study, we evaluated the visual function parameters and assessed the association between visual dysfunction and morphologic changes in the retina of 37 patients with PD. Parameters corresponding to VA at different contrast levels, and all CSV tests results were altered in PD patients in comparison with healthy subjects, prior to and after statistical correction for multiple tests. Moreover, contrast sensitivity was the most affected parameter in our study and correlated with most of the structural data. Color vision was measured with two different tests, the Farnsworth and L'Anthony 15 D tests. These tests provide information for differentiating subjects with severe loss of color vision from those with milder color defects or normal color vision, and also can be used to evaluate acquired loss of color vision. In our study, only the L'Anthony Confusion Angle was significantly altered in PD patients. L'Anthony test is less saturated than the Farnsworth color test, thus it is designed to detect more subtle color deficiencies. Our patients performed worse than controls in both tests (higher C-index and S-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

index, reaching ranges similar to protanomalies) although these differences did not reach statistical significance as established by Bonferroni correction. L'Anthony S-index p value was <0.05, indicating that our patients had a (subtle) tendency to protanomaly (S-index of 1.95).

In this study only one eye was tested per person. Some recent studies suggest asymmetrical involvement of the retina in PD and accept the incorporation of both eyes of each patient in the study.[21] Thus, the diagnostic yield in this study may have been lowered by including a potentially lesser affected eye. However, incorporating both eyes of a patient may sometimes be controversial: a minimum symmetric structural and functional alterations could have been masked and generated a % of dependence between measurements. The majority of authors consider the inclusion of only one eye of each patient adequate for statistical analysis because RNFL measurements correlate significantly between the two eyes; therefore, we included only one eye per patient.

Previous studies have indicated that PD patients lose foveal contrast sensitivity to patterns to which normal observers are most sensitive (i.e., requiring the least contrast for detection).[8,9] Ganglion cells in the retina show adaptation to visual contrast and pool visual inputs over their receptive fields through an array of parallel bipolar cells with smaller receptive fields.[22] The parvo- and magnocellular ganglion cells are located in the RGC layer and take two different pathways for the identification of color and contrast at different frequencies.[23] RGC loss (as observed using SD-OCT) was recently identified as the cause of visual impairment in patients suffering from another neurodegenerative process, multiple sclerosis.[24] Thus, a similar process could be the cause of the contrast and color deficiencies in patients with PD. In addition, in the mammalian retina, color vision and contrast sensitivity are modulated through D1 and D2 receptors. These dopaminergic receptors are differentially located in the retinal layers and a

complete lack of activation leads to signal dispersion and alterations in color vision and contrast sensitivity.[2]

Alteration of the retinal layers in PD was first demonstrated in 2004.[25] Since then, various studies have demonstrated different results.[3-5,25-28] Previous studies performed by our team confirmed that both macular thickness and the RNFL were affected in patients with PD, especially in the inferior and temporal quadrants.[4,5, 29] Moreover, Garcia-Martin et al demonstrated that the inner retinal layers were most affected in these patients, and that the GCL thickness was inversely correlated with disease duration and PD severity, and was predictive of axonal damage in these patients.[30] The present study included a smaller number of patients, which may have affected the significance of our results compared to previous studies. We could only detect a significant reduction in the minimum GCL+IPL thickness in PD patients compared to healthy subjects, after correction for multiple comparisons (using Bonferroni test). However, we detected a clear tendency towards a reduction in the macular, RNFL, and GCL thicknesses ($p<0.05$). A significant reduction in the temporal sectors of the peripapillary RNFL thickness has been repeatedly observed by different groups [31, 32] and was confirmed in the present study. Two recent studies, however, detected no differences in the peripapillary RNFL thickness of PD patients compared to healthy controls using SD-OCT [27,28] and one study only found significant differences in the nasal quadrant.[33] More studies are required to clarify these contradictory observations.

In a previous study, we demonstrated that the retinal thickness corresponding to the papillomacular bundle (as measured with the Axonal Analytics software for Spectralis OCT) correlated ($r>0.70$) with some functional parameters (such as the mean defect and the pattern standard deviation of the automated perimetry) in patients with PD.[34] The GCL was not

1
2
3
4
5
6
7
8
9 310 investigated at that time, however, and visual function parameters were reduced to perimetry and
10 311 color vision measured with the Ishihara color test. The current study evaluated not only the
11 312 RNFL but also the GCL thickness, and more visual function parameters were analyzed. The
12 313 GCL correlated most with the visual function parameters: GCL thickness was directly associated
13 314 with VA and CSV measured at all different spatial frequencies, and inversely correlated with the
14 315 color vision indexes. Thus, GCL thinning is linked to color deficiencies, contrast sensitivity loss,
15 316 and lower vision at different contrast levels in PD patients.
16
17 317 The degree of correlation is usually classified as low (<0.30), moderate ($0.30-0.70$), or strong
18 318 (>0.70). Our results revealed a low and moderate degree of correlation between most parameters,
19 319 consistent with findings in other neurodegenerative diseases.[35] Macular thickness and macular
20 320 volume, however, were strongly associated with functional parameters (VA, CS, and L'Anthony
21 321 CCI, C-index, and S-index). This strong association, to the best of our knowledge, has not been
22 322 previously demonstrated in PD.
23
24 323 There are very few studies of the correlation between functional and structural parameters in PD
25 324 patients. Adam et al [14] demonstrated a significant reduction in the inner retinal layer complex
26 325 (RNFL + GCL + IPL) in PD patients, but no association with contrast sensitivity (measured with
27 326 the Pelli Robson chart). A very recent study by Kaur et al [15] demonstrated a correlation
28 327 between functional parameters and GCL thinning, consistent with our results. Kaur et al,
29 328 however, found no significant alterations in VA or color vision in PD patients and the severity of
30 329 the disease was not correlated with structural parameters, in contrast to other studies that
31 330 demonstrate an association between macular and GCL thickness and disease duration and
32 331 severity.[29,30] Although the severity of the disease in our sample (based on the Hoehn Yahr
33 332 scale) was similar to that in Kaur's study, the duration of the disease in our study was higher than

that in Kaur's patients (13 years vs 5 years), which may account for some of the differences in the results between the two studies. These discrepancies (and similarities) support the need for more studies on this topic. Our results, together with previously published studies,[15, 30] suggest that the GCL could be a reliable indicator of structural alterations in the retina of PD patients, demonstrating a significant correlation with functional tests in these patients. The results of the present study have important implications for clinical diagnosis and functional deficits in patients with PD, and highlight the importance of visual function tests in the evaluation of these patients.

In conclusion, visual dysfunction was significantly correlated with morphologic parameters in PD patients. PD patients present with a reduction in macular, RNFL, and GCL thickness, with changes in the GCL being most closely associated with visual dysfunction.

Contributorship:

V. Polo: Research project: organization. Statistical analysis and Manuscript: Review and critique.

M. Satue: Research project: Conception, design, organization and execution. Statistical analysis: Review and critique. Manuscript: Writing of the first draft, review and critique.

MJ Rodrigo: Research project: organization and execution. Statistical analysis: Review and critique. Manuscript: Writing of the first draft, review and critique.

S. Otin: Research project: organization and execution. Statistical analysis: Review and critique. Manuscript: review and critique.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

R. Alarcia: Research project: organization and execution. Statistical analysis: Review and critique. Manuscript: review and critique.

MP. Bambo: Research project: execution. Statistical analysis: Review and critique. Manuscript: review and critique.

MI. Fuertes: Research project: execution. Statistical analysis: Review and critique. Manuscript: review and critique.

JM. Larrosa: Research project: execution. Statistical analysis: Review and critique. Manuscript: review and critique.

LE. Pablo: Research project: execution. Statistical analysis: Review and critique. Manuscript: review and critique.

E. Garcia-Martin: Research project: Conception, design, organization and execution. Statistical analysis: Design, execution, review and critique. Manuscript: Writing of the first draft, review and critique.

Competing interests and funding

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

The authors disclose no conflict of interest.

Data sharing

All relevant data are included in this manuscript. No additional data available.

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

References

1. Bodis-Wollner I. Retinopathy in Parkinson disease. J Neural Transm 2009;116:1493-501.

2. Hajee ME, March WF, Lazzaro DR et al. Inner retinal layer thinning in Parkinson’s disease. Arch Ophthalmol 2009;127:737-41.

3. Cubo E, Tedejo RP, Rodriguez Mendez V. Retina thickness in Parkinson’s disease and essential tremor. Mov Disord 2010;25:2461-77.

4. Satue M, Garcia-Martin E, Fuertes I et al. Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson’s disease patients. Eye (Lond) 2013;27:507-14.

5. Garcia-Martin E, Satue M, Fuertes I et al. Ability and reproducibility of Fourier domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson’s disease. Ophthalmology 2012;119:2161-7.

6. Fisher JB, Jacobs DA, Markowitz CE et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. Ophthalmology 2006;113:324.

7. Parisi V, Manni G, Spadaro M et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. Invest Ophthalmol Vis Sci 1999;40:2520-7.

8. Bodis-Wollner I. Visual acuity and contrast sensitivity in patients with cerebral lesions. Science 1972;178:769-71.

9. Bodis-Wollner I, Diamond S. The measurement of spatial contrast sensitivity in cases of blurred vision associated with cerebral lesions. Brain 1976;99:695-710.

10. Price MJ, Feldman RG, Adelberg D et al. Abnormalities in color vision and contrast sensitivity in Parkinson’s disease. Neurology 1992;42:887-90.

- 1
2
3
4
5
6
7
8
9 400 11. Oh YS, Kim JS, Chung SW et al. Color vision in Parkinson's disease and essential tremor.
10 401 European Journal of Neurology 2011;18: 577-83.
11
12 402 12. Hipp G, Diederichs NJ, Pieria V et al. Primary vision and facial emotion recognition in early
13 403 Parkinson's disease. Journal of the Neurological Sciences 2014;338 :178-82.
14
15 404 13. Archibald NK, Clarke MP, Mosimann UP et al. Retinal thickness in Parkinson's disease.
16 405 Parkinsonism Relat Disord 2011; 17(6):431-6.
17
18 406 14. Adam CR1, Shrier E, Ding Y et al. Correlation of inner retinal thickness evaluated by
19 407 spectral-domain optical coherence tomography and contrast sensitivity in Parkinson disease. J
20 408 Neuroophthalmol. 2013;33(2):137-42.
21
22 409 15. Kaur M, Saxena R, Singh D et al. Correlation Between Structural and Functional Retinal
23 410 Changes in Parkinson Disease. J Neuroophthalmol 2015 [Epub ahead of print]
24
25 411 16. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol
26 412 1999;56:33-9.
27
28 413 17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology
29 414 1967;17:427-42.
30
31 415 18. Ramaker C, Marinus J, Stiggelbout AM, et al. Systematic evaluation of rating scales for
32 416 impairment and disability in Parkinson's disease. Mov Disord 2002;17(5):867-76.
33
34 417 19. Vingrys AJ, King-Smith PE. A quantitative scoring technique for panel tests of color vision.
35 418 Invest Ophthalmol Vis Sci 1988;29(1):50-63.
36
37 419 20. Bowman AJ. A method for quantitative scoring of the Farnsworth panel D15. Acta
38 420 Ophthalmologica 1982;60:907-16.
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21. Shrier EM, Adam CR, Spund B, Glazman S, Bodis-Wollner I. Interocular Asymmetry of Foveal Thickness in Parkinson Disease. *J Ophthalmol.* 2012; 2012:728457

22. Kim, KJ, Rieke, F. Temporal contrast adaptation in the input and output signals of salamander retinal ganglion cells. *J. Neurosci* 2001;21:287-99.

23. Laycock R, Crewther SG, Crewther DP. A role for the ‘magnocellular advantage’ in visual impairments in neurodevelopmental and psychiatric disorders. *Neurosci Biobehav Rev.* 2007;31:363-76.

24. Lampert EJ, Andorra M, Torres-Torres R, et al. Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. *J Neurol.* 2015 [Epub ahead of print]

25. Inzelberg R, Ramirez JA, Nisipeanu P et al. Retinal nerve fiber layer thinning in Parkinson’s disease. *Vision Res* 2004;44:2793-7.

26. Altıntaş O, Işeri P, Ozkan B et al. Correlation between retinal morphological and functional findings and clinical severity in Parkinson’s disease. *Doc Ophthalmol* 2008;116:137-46.

27. Bittersohl D, Stemplewitz B, Keserü M et al. Detection of retinal changes in idiopathic Parkinson's disease using high-resolution optical coherence tomography and Heidelberg retina tomography. *Acta Ophthalmol.* 2015;93(7):e578-84.

28. Chorostecki J, Seraji-Bozorgzad N, Shah A et al. Characterization of retinal architecture in Parkinson's disease. *J Neurol Sci.* 2015;355(1-2):44-8.

29. Satue M, Seral M, Otin S et al. Retinal thinning and correlation with functional disability in patients with Parkinson's disease. *Br J Ophthalmol* 2014;98(3):350-5.

- 441 30. Garcia-Martin E, Larrosa JM, Polo V et al. Distribution of retinal layer atrophy in patients
442 with Parkinson disease and association with disease severity and duration. *Am J Ophthalmol*
443 2014;157(2):470-8.
- 444 31. Sari ES, Koc R, Yazici A, Sahin G, Ermis SS. Ganglion cell-inner plexiform layer thickness
445 in patients with Parkinson disease and association with disease severity and duration. *J*
446 *Neuroophthalmol*. 2015;35(2):117-21.
- 447 32. La Morgia C, Barboni P, Rizzo G et al. Loss of temporal retinal nerve fibers in Parkinson
448 disease: a mitochondrial pattern? *Eur J Neurol*. 2013;20(1):198-201
- 449 33. Bayhan HA, Aslan Bayhan S, Tanik N, Gurdal C. The association of spectral-domain optical
450 coherence tomography determined ganglion cell complex parameters and disease severity in
451 Parkinson's disease. *Curr Eye Res*. 2014;39(11):1117-22.
- 452 34. Satue M, Bambo M, Garcia-Martin E, et al. Correlation between function and structure of
453 retinal nerve fiber layer in Parkinson disease. *Acta Ophthalmologica*. 2012;90:0.
- 454 35. Garcia-Martin E, Rodriguez-Mena D, Herrero R, et al. Neuro-ophthalmologic
455 evaluation, quality of life and functional disability in MS patients. *Neurology*
456 2013;81:1-8.

457

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends

Figure 1: Correlation between the average macular thickness and contrast sensitivity vision as measured with the CSV 1000E test, at a spatial frequency of 6 cycles per degree, in patients with Parkinson’s disease.

Figure 2: Correlation between the average macular thickness and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson’s disease.

Figure 3: Correlation between macular volume and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson’s disease.

Table 1: Epidemiologic and disease characteristics of patients with PD and healthy subjects, and statistical significance (P). Abbreviations: SD, standard deviation; UPDRS III, Unified Parkinson Disease Rating Scale part III.

Table 2: Mean and standard deviation (SD) of visual functional parameters in healthy controls and subjects with Parkinson disease. **Results in bold letters indicate statistical significance** (~~p<0.05~~). The asterisk indicates those values with statistical significance after Bonferroni correction for multiple tests (p<0.0125 for VA ETDRS 100, 2.50 and 1.25; p<0.0125 for Pelli Robson and CSV 1000E measurements; p<0.0083 for Farnsworth and L’Anthony tests). Bold letters indicate parameters with p value <0.05. Abbreviations: VA, visual acuity; ETDRS, early treatment diabetic retinopathy study; cpd, cycles per degree; AC CCI, age corrected color

confusion index; CCI, color confusion index; C-index, confusion index; Conf Angle, confusion angle; S-index, scatter index; PD, Parkinson disease.

Table 3: Mean and standard deviation (SD) of structural parameters (retinal nerve fiber layer, ganglion cell layer and macular thicknesses) obtained with the Cirrus HD optical coherence tomography device in healthy controls and subjects with Parkinson disease. **Bold letters indicate statistical significance ($p < 0.05$).** The asterisk indicates those values with statistical significance after Bonferroni correction for multiple tests ($p < 0.0055$ for macular measurements; $p < 0.0062$ for ganglion cell measurements and $p < 0.01$ for RNFL measurements). Bold letters indicate parameters with p value < 0.05 . Abbreviations: IPL, inner plexiform layer; GCL, ganglion cell layer; RNFL, retinal nerve fiber layer; HD, high definition.

Formatted: Font: (Default) Times New Roman, 12 pt, (Asian) Japanese, Kern at pt

Formatted: Font: (Default) Times New Roman, 12 pt, (Asian) Japanese, Kern at pt

Table 4: Correlation between macular and ganglion cell layer structural measurements and color vision evaluated with L'Anthony color test in patients with Parkinson disease. Data in bold type correspond to statistically significant correlations (p value < 0.05). Abbreviations: GCL, ganglion cell layer; IPL, inner plexiform layer; C-index, Confusion index; CCI, color confusion index; S-index, Scatter index.

Table 5: Correlation between visual acuity measured with ETDRS chart at different levels of contrast (in %) and macular structural measurements (thickness and volume) in patients with Parkinson disease. Correlation data in bold type are statistically significant (p value < 0.05). Abbreviations: VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.

1
2
3
4
5
6
7
8
9 503
10
11 504
12
13 505
14
15 506
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1: Correlation between the average macular thickness and contrast sensitivity vision as measured with the CSV 1000E test, at a spatial frequency of 6 cycles per degree, in patients with Parkinson's disease. 108x83mm (300 x 300 DPI)




Figure 2: Correlation between the average macular thickness and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson's disease. 118x100mm (300 x 300 DPI)




Figure 3: Correlation between macular volume and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson's disease.
119x102mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract Check. This included in the abstract, methods, line 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Check. This is included in the abstract. Methods, from line 2 to results section line 9
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Check. This is included in the introduction. Paragraph 2.
Objectives	3	State specific objectives, including any prespecified hypotheses Check. This is included in the introduction. Paragraph 3.
Methods		
Study design	4	Present key elements of study design early in the paper Check. This is included in Methods, paragraph 1-3.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Check. This is included in Methods, paragraph 1-3.
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Check. This is included in Methods, paragraph 2
		(b) For matched studies, give matching criteria and the number of controls per case Check. This is included in Methods, paragraph 1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Check. Outcomes and variables are explained in Methods, paragraphs 4-8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Check. Details of measurements are included in paragraphs 4-8.
Bias	9	Describe any efforts to address potential sources of bias Check. This is included in paragraph 8, line 3-4.
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Check. Quantitative variables are explained in Methods, paragraphs 4-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding. Check. This is included in methods, paragraph 9
		(b) Describe any methods used to examine subgroups and interactions. Not applicable.
		(c) Explain how missing data were addressed Not applicable
		(d) If applicable, explain how matching of cases and controls was addressed Not applicable
		(e) Describe any sensitivity analyses Not applicable

Results

Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</p> <hr/> <p>(b) Give reasons for non-participation at each stage</p> <hr/> <p>(c) Consider use of a flow diagram</p> <p>This is a cross sectional study. Inclusion criteria were explained in methods. All eligible subjects were included in the study (37) as already explained, all completed the evaluation.</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Check. This is included in Results, paragraph 1-2 and table 1.</p> <hr/> <p>(b) Indicate number of participants with missing data for each variable of interest</p> <p>Not applicable.</p>
Outcome data	15*	<p>Report numbers in each exposure category, or summary measures of exposure</p> <p>Check. Numbers and results of each variable are included in results.</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>Check. Main results include statistical results prior and post multiple comparisons adjustment.</p> <hr/> <p>(b) Report category boundaries when continuous variables were categorized Check. Category of correlation is explained in discussion, paragraph 5</p> <hr/> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Not applicable</p>

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Not applicable
Discussion		
Key results	18	Summarise key results with reference to study objectives Check. This is included in results, paragraph 1.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Check, this is mentioned in paragraph 3 and 6.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Check. This is included and discussed along the discussion section.
Generalisability	21	Discuss the generalisability (external validity) of the study results Check. This is included and discussed along the discussion section
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Check. Not applicable.

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Visual dysfunction and its correlation with retinal changes in patients with Parkinson's disease: an observational cross-sectional study

Journal:	BMJ Open
Manuscript ID	bmjopen-2015-009658.R3
Article Type:	Research
Date Submitted by the Author:	03-Mar-2016
Complete List of Authors:	Polo, Vicente; Miguel Servet University Hospital, Ophthalmology Satue, Maria; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Rodrigo, Maria Jesus; Miguel Servet University Hospital, Ophthalmology Otin, Sofia; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Alarcia, Raquel; Miguel Servet University Hospital, Neurology Bambo, Maria; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Fuertes, Isabel; Miguel Servet University Hospital, Ophthalmology; Aragon Institute of Health Science, Larrosa, Jose; Hospital Universitario Miguel Servet, Ophthalmology; Institute for Sanitary Research of Aragon (IISA), Pablo, Luis; Miguel servet University Hospital, Ophthalmology; Institute for Sanitary Research of Aragon (IISA), Garcia-Martin, Elena; Miguel Servet University Hospital, Ophthalmology; Institute for Sanitary Research of Aragon (IISA),
Primary Subject Heading:	Ophthalmology
Secondary Subject Heading:	Ophthalmology, Neurology
Keywords:	Neuro-ophthalmology < NEUROLOGY, Parkinson-s disease < NEUROLOGY, Neuro-ophthalmology < OPHTHALMOLOGY

SCHOLARONE™
Manuscripts

Visual dysfunction and its correlation with retinal changes in patients with Parkinson's disease: an observational cross-sectional study

AUTHORS:

Polo V^{1,2}, Satue M^{1,2}, Rodrigo MJ¹, Otin S^{1,2}, Alarcia R^{1,3}, Bambo MP^{1,2}, Fuertes MI^{1,2}, Larrosa JM^{1,2}, Pablo LE^{1,2}, Garcia-Martin E^{1,2}.

AFFILIATIONS:

- ¹ IIS Aragon. Insitute for Health Sciencies of Aragon, Zaragoza, Spain.
- ² Ophthalmology Department, Miguel Servet University Hospital, Zaragoza, Spain.
- ³ Neurology Department, Miguel Servet University Hospital, Zaragoza, Spain.

CORRESPONDENCE:

Maria Satue
C/ Padre Arrupe. Consultas Externas de Oftalmología 50009-Zaragoza (Spain)
Email: mariasatue@gmail.com Telephone: 0034.976.76.55.58

RUNNING TITLE: OCT and visual dysfunction in Parkinson disease.

STUDY DESIGN AND SETTING: An observational cross-sectional study, carried out at Miguel Servet University Hospital, in Zaragoza, Spain.

KEY WORDS: Parkinson disease, visual function, contrast sensitivity, ganglion cell layer.

WORD COUNT: 2500 words.

All subjects provided detailed consent to participate in this study, which was conducted in accordance with the guidelines established by the Ethics Committee of the Miguel Servet Hospital and based on the principles of the Declaration of Helsinki.

This research received no specific grant from any funding agency in the public, commercial or not-for-profit sectors.

26 The authors disclose no conflict of interest.

27

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SUBTITLE: Visual acuity, contrast sensitivity vision and color vision are affected in Parkinson disease. Visual dysfunction in these patients correlates with structural changes in the retina measured with Spectral domain OCT.

For peer review only

Abstract

Objectives: To evaluate visual dysfunction and its correlation with structural changes in the retina in patients with Parkinson disease (PD).

Methods: Patients with PD (n=37) and controls (n=37) were included in an observational cross-sectional study and underwent visual acuity (VA), color vision (using the Farnsworth and L'Anthony desaturated D15 color tests), and contrast sensitivity vision (CSV; using the Pelli Robson chart and CSV 1000E test) evaluation to measure visual dysfunction. Structural measurements of the retinal nerve fiber layer (RNFL), and macular and ganglion cell layer (GCL) thicknesses were obtained using spectral domain optical coherence tomography (SD-OCT). Comparison of obtained data and correlation analysis between functional and structural results were performed.

Results: VA (in all different contrast levels) and all CSV spatial frequencies were significantly worse in PD patients than in controls. Color vision was significantly affected based on the L'Anthony color test. Significant GCL loss was observed in the minimum GCL + inner plexiform layer. A clear tendency towards a reduction in several macular sectors (central, outer inferior, outer temporal and superior [inner and outer]) and in the temporal quadrant of the RNFL thickness was observed, although the difference was not significant. CSV was the functional parameter most strongly correlated with structural measurements in PD. Color vision was associated with most GCL measurements. Macular thickness was strongly correlated with macular volume and functional parameters ($r > 0.70$, $p < 0.05$).

Conclusions: Patients with PD had visual dysfunction that correlated with structural changes evaluated by SD-OCT. GCL measurements may be reliable indicators of visual impairment in PD patients.

Strengths and limitations of this study:

The strengths of this study should be resumed by the following bullet points:

- This study includes a complete assessment of visual function parameters and the evaluation of different retinal structures using Spectral domain Optical coherence tomography in patients with Parkinson disease.
- There are only 2 other published articles evaluating the association between visual dysfunction and morphologic parameters. Results provided by these previous studies differ from our results, possibly due to different measurement methods and sample size.
- Color vision in our study was assessed by L'Anthony and Farnsworth D15 color tests, which may provide more specific information about color deficiencies. These tests are not commonly used to evaluate color deficiencies in PD patients.
- As an important limitation to our study, we included one randomly selected eye per patient. The incorporation of both eyes of each patient in Parkinson disease studies is usually recommended due to asymmetrical involvement of the retina in this process.

75

76 **Introduction**

77 Foveal vision alterations are associated with Parkinson disease (PD), and seem to be caused by
78 dysfunction of the intraretinal dopaminergic circuitry and final retinal output to the brain.[1]
79 Recent studies demonstrated retinal thinning in PD patients compared with healthy subjects.[2-5]
80 Several studies report a correlation between functional disability and axonal loss observed in the
81 optic nerve in multiple sclerosis, another neurodegenerative process.[6,7] PD patients are also
82 reported to have decreased contrast sensitivity and color vision, and altered visual evoked
83 potentials.[1,8-13] To our knowledge, however, very few studies have assessed visual
84 dysfunction in PD and its correlation with morphologic parameters.[14,15]
85 In the present study, we evaluated visual acuity (VA) using an Early Treatment Diabetic
86 Retinopathy Study (ETDRS) chart, contrast sensitivity vision (CSV) using the CSV-1000E test
87 and Pelli-Robson chart, and color vision using the Farnsworth and L'Anthony tests in PD
88 patients and healthy controls to examine the association between visual dysfunction and
89 morphologic parameters.

90

91 **Material and methods**

92 Thirty-seven eyes of 37 patients with definite PD and 37 eyes of 37 age- and sex-matched
93 healthy individuals were recruited for an observational cross-sectional study. The study was
94 performed at Miguel Servet University Hospital in Zaragoza, Spain, and all evaluations were
95 performed in one single visit. All procedures adhered to the tenets of the Declaration of Helsinki,
96 and all participants provided informed consent to participate in the study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

The diagnosis of PD was based on standard clinical and neuroimaging criteria.[16] Information about disease severity was assessed using the Hoehn Yahr scale [17] and the Unified Parkinson Disease Rating Scale part III score (UPDRS III) [18]. Disease duration and treatment were recorded. Exclusion criteria were the presence of significant refractive errors (>5 diopters of spherical equivalent refraction or 3 diopters of astigmatism); intraocular pressure ≥ 21 mmHg; media opacifications; concomitant ocular diseases, including history of glaucoma or retinal pathology; and systemic conditions that could affect the visual system. The healthy controls had no history and no evidence of ocular or neurologic disease of any nature; their best-corrected visual acuity (BCVA) was >20/30 based on the Snellen scale.

All subjects underwent a complete neuro-ophthalmic evaluation that included pupillary, anterior segment, and funduscopy examination. Visual function was assessed by evaluating BCVA using an ETDRS chart, CSV using the CVS-1000E test and Pelli-Robson chart, and color vision using the Farnsworth desaturated D15 and L'Anthony desaturated D15 tests. Structural analysis of the retina was performed using Spectral domain (SD) optical coherence tomography (OCT) with the Cirrus High definition (HD) OCT (Carl Zeiss Meditec Inc, Dublin, CA), which included three different protocols: macular protocol (for macular thickness analysis), RNFL protocol, and ganglion cell protocol (for individual analysis of this layer).

LogMAR visual acuity (VA) was evaluated at three different contrast levels: 100% (HCVA, using ETDRS chart), 2.50%, and 1.25% (LCVA, using Low-Contrast Sloan Letter Charts - Precision Vision, LaSalle, IL-), The percentage indicating the level of contrast, i.e., 100% representing black letters over white background and 1.25% light grey letters over white background. All measurements were obtained under monocular vision and controlled lighting conditions with best correction.

1
2
3 120 Contrast sensitivity provides more complete information about visual function than visual acuity
4
5
6 121 tests. CSV was evaluated in our patients using the Pelli-Robson chart and the CVS-1000E test.
7
8 122 The Pelli-Robson chart comprises horizontal lines of capital letters organized into groups of
9
10 123 three (triplets) with two triplets per line. Within each triplet, all letters have the same contrast.
11
12 124 The contrast decreases from one triplet to the next, even within each line. All patients were
13
14 125 evaluated under both monocular and binocular vision at a distance of 1 meter from the chart and
15
16 126 under controlled photopic conditions (85 cd/m²). The score corresponding to the last triplet of
17
18 127 letters seen by the patient was recorded.
19
20
21
22 128 The CSV-1000E instrument is used worldwide for standardized CSV and glare testing. All
23
24 129 patients were evaluated at a distance of 2.5 meters from the chart under monocular vision at 4
25
26 130 different spatial frequencies (3, 6, 12, and 18 cycles per degree [cpd]). The chart comprises four
27
28 131 rows with 17 circular patches each. The patches present a grating that decreases in contrast
29
30 132 moving from left to right across the row. The patient indicates whether the grating appears in the
31
32 133 top patch or the bottom patch for each column. Each contrast value for each spatial frequency
33
34 134 was transformed into a logarithmic scale according to standardized values.
35
36
37
38
39 135 Color vision was assessed using the Color Vision Recorder (CVR) program. CVR software
40
41 136 analyzes chromatic discrimination by classification of colors. The program includes the classic
42
43 137 test of Farnsworth 100-hue (FM-100), Farnsworth - Munsell D15, and L'Anthony D15. All
44
45 138 patients in the study were evaluated using the Farnsworth - Munsell D15 and L'Anthony D15
46
47 139 protocols and different output parameters such as the Confusion Index (C-index), the Color
48
49 140 Confusion Index (CCI), the Confusion angle (Conf Ang), and the Scatter Index (S-index) were
50
51 141 recorded.[19,20] The tests were performed under monocular vision.
52
53
54
55
56
57
58
59
60

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

142 Structural measurements of the retina were obtained using the Cirrus OCT device. The same
143 experienced operator performed all scans and did not apply manual correction to the OCT
144 output. We used an internal fixation target because it provides the highest reproducibility and
145 rejected poor quality scans prior to data analysis. The Cirrus OCT macular cube 512 x 128
146 protocol provides a macular volume measure and retinal thickness values for nine areas. These
147 areas include a central 1-mm circle representing the fovea, and inner and outer rings measuring 3
148 mm and 6 mm in diameter, respectively. The inner and outer rings are divided into four
149 quadrants each. The Cirrus OCT optic disc protocol generates images with 200 linear scans
150 enabling analysis of the RNFL of a 6-mm³ area around the optic nerve. For each scan series of
151 RNFL measurements, we assessed the average, superior, inferior, temporal, and nasal thickness.
152 Cirrus segmentation analysis for retinal layers also provides measurements of the GCL thickness,
153 evaluating six areas of the macular cube (superior, superonasal, inferonasal, inferior,
154 inferotemporal, and superotemporal sectors) and measurements of the average and minimum
155 GCL plus the inner plexiform layer (GCL + IPL) value of a set of 360 spokes, where each
156 average represents the mean number of the pixels along that spoke that lies within the
157 measurement annulus. The minimum is selected because the thinnest portion of the GCL + IPL
158 in the perifoveal region is considered to indicate damage to the ganglion cells.

159 All data analyses were performed using SPSS software version 20.0 (SPSS Inc., Chicago, IL).
160 Due to the parametric distribution of the data, differences between evaluations of PD patients
161 and healthy subjects were compared using Student's t-test. To avoid a high false positive rate,
162 the Bonferroni correction for multiple comparisons was calculated. The level of significance for
163 each variable was established based on Bonferroni calculations.

The linear correlation between structural and functional parameters was determined using Pearson's correlation coefficient. Values of $p < 0.05$ were considered to indicate a significant correlation. Each eye was considered separately, and one eye from each patient was randomly selected for analysis.

Results

Thirty-seven patients with PD and 37 healthy controls were included in the study. The mean age of the patients with PD was 69 years (range: 58–74 years) and the mean age of the healthy controls was 68 years (range: 60–76 years). Age ($p=0.361$), sex ($p=0.441$), and intraocular pressure ($p=0.720$) did not differ significantly between healthy controls and patients with PD. Mean time from diagnosis of PD was 13.2 years. The median Hoehn Yahr stage was 2.7, and the stage of PD based on the UPDRS III was 25.06 (range: 7-39; Table 1).

Treatment was divided into three different categories: "Drugs that enhance dopamine levels" (carbidopa, levodopa and rasagiline), "dopaminergic drugs" (pramipexole, ropirinol, rotigotine), and "other" (amitriptyline, propranolol, clonazepam). "Drugs that enhance dopamine levels" was the most prescribed category (89% of patients) and combination therapy with levodopa and carbidopa was the most frequent treatment (44%). Sixty-four percent of treatments were categorized as "dopaminergic", most of which were used in combination with drugs included in the previous category. A small percentage of patients (9%) were prescribed drugs with no dopaminergic effects.

PARAMETER	CONTROLS	PARKINSON DISEASE	p
Number of eyes (n)	37	37	-
Age, years, range	68 (60–76)	69 (58–74)	0.361
Men:Women (% of men)	24:13 (64.9)	23:14 (62.2)	0.441
Intraocular Pressure	15.58 (2.71)	15.12 (2.98)	0.720
Disease duration, years, mean (SD)	-	13.2 (5.77)	-
Hoehn Yahr, mean (SD)	-	2.7 (0.64)	-
UPDRS III, mean (SD)	-	25.06 (8.24)	-

Table 1.

Functional parameters

PD patients had a lower BCVA at all three contrast levels of the ETDRS chart compared to the controls (0.18 ± 0.26 in patients vs -0.065 ± 0.9 in controls at 100%, $p=0.001$; 0.59 ± 0.21 vs 0.44 ± 0.13 at 2.50%, $p=0.010$; and 0.61 ± 0.23 vs 0.58 ± 0.16 at 1.25%, $p=0.009$). CSV was affected in patients at all four spatial frequencies of the CSV 1000E chart (3, 6, 12, and 18 cpd) when analyzed based on the number of correct localized gratings ($p=0.001$, <0.001 , <0.001 , and 0.004 respectively). The Pelli Robson results also revealed a significant reduction in CSV in PD patients (1.71 in patients vs 1.89 in controls, $p=0.02$). Color vision (Conf Angle in L'Anthony test) was also affected in PD. The results are shown in Table 2.

	HEALTHY CONTROLS		PARKINSON DISEASE PATIENTS		SIGNIFICANCE (P)
	Mean	SD	Mean	SD	
VA ETDRS 100	-0.06	0.096	0.18	0.26	0.001*
VA ETDRS 2.5	0.44	0.13	0.59	0.22	0.010*
VA ETDRS 1.25	0.58	0.16	0.62	0.23	0.009*
Pelli Robson	1.89	0.11	1.71	0.17	0.002*
CSV 1000 3 cpd	1.72	0.16	1.49	0.35	0.001*
CSV 1000 6 cpd	1.94	0.13	1.62	0.34	<0.001*
CSV 1000 12 cpd	1.62	0.17	1.26	0.41	<0.001*
CSV 1000 18 cpd	1.11	0.22	0.73	0.34	0.004*
Farnsworth AC CCI	1.11	0.22	0.73	0.34	0.851
Farnsworth C- index	1.10	0.20	1.24	0.42	0.093
Farnsworth CCI	1.07	0.12	1.14	0.24	0.110
Farnsworth Conf Angle	63.90	11.15	65.84	7.49	0.392
Farnsworth S-index	1.56	0.22	1.64	0.39	0.278
Farnsworth time	78.67	28.96	82.91	33.10	0.616
L'Anthony AC CCI	1.05	0.19	1.02	0.18	0.489
L'Anthony C-index	1.43	0.39	1.64	0.53	0.058
L'Anthony CCI	1.30	0.23	1.44	0.37	0.066
L'Anthony Conf Angle	62.31	14.74	71.91	9.25	0.002*
L'Anthony S-index	1.69	0.43	1.95	0.48	0.020
L'Anthony time	77.14	25.99	84.09	39.31	0.431

Table 2

Structural parameters

Based on Bonferroni corrections, OCT measurements indicated a significant difference in the minimum GCL+IPL value ($80.18 \pm 6.19 \mu\text{m}$ vs $82.45 \pm 3.60 \mu\text{m}$; $p=0.005$). However, we observed a clear tendency towards a reduction in superior macular sectors, in the outer inferior, outer temporal, and central macular thickness in PD patients compared to controls: the p value for these variables was <0.05 but did not meet Bonferroni significance (results are shown in Table

2). The segmentation analysis revealed a tendency towards reduced GCL in PD patients in the superior ($81.64\pm7.08\text{ }\mu\text{m}$ in patients vs $84.55\pm4.32\text{ }\mu\text{m}$ in controls; $p=0.032$) and superonasal sectors ($81.04\pm7.23\text{ }\mu\text{m}$ vs $85.28\pm4.78\text{ }\mu\text{m}$; $p=0.029$); and the RNFL was reduced in the temporal quadrant in PD patients (Table 3). These parameters however, did not meet the level of significance established by Bonferroni correction.

	CONTROLS		PARKINSON DISEASE		P
	Mean	SD	Mean	SD	
Structural parameters					
<i>Macular measurements</i>					
Central macular thickness	254.75	17.903	248.96	17.765	0.028
Inner superior macular thickness	327.34	13.094	325.73	19.329	0.019
Inner nasal macular thickness	328.52	13.263	325.45	17.098	0.091
Inner inferior macular thickness	326.14	13.179	324.82	17.921	0.106
Inner temporal macular thickness	315.90	13.615	312.82	15.760	0.945
Outer superior macular thickness	284.76	9.418	279.44	17.981	0.008
Outer nasal macular thickness	302.41	12.167	299.18	17.064	0.074
Outer inferior macular thickness	277.79	10.755	273.76	16.798	0.045
Outer temporal macular thickness	271.52	10.992	266.23	18.987	0.013
<i>Ganglion cell layer thickness</i>					
Superior	84.55	4.323	81.61	7.087	0.032
Superonasal	85.28	4.780	81.04	7.234	0.029
Inferonasal	84.66	5.314	81.82	7.521	0.135
Inferior	84.34	5.052	81.91	6.252	0.389
Inferotemporal	85.79	4.003	83.73	4.860	0.233
Temporal	83.76	3.324	82.27	5.312	0.069
Average IPL+GCL	84.83	4.071	82.73	6.230	0.095
Min IPL+ GCL	82.45	3.601	80.18	6.194	0.005*
<i>RNFL thickness</i>					
Average	96.17	6.714	94.88	11.505	0.105
Superior	117.90	10.965	118.68	16.861	0.115
Nasal	73.59	12.724	72.40	15.182	0.345
Inferior	128.14	14.060	123.20	22.907	0.075
Temporal	64.97	8.218	61.48	10.553	0.027

Table 3

216 *Correlation between functional and structural parameters*

217 CSV was the functional parameter most frequently associated with structural measurements in
218 PD. The Pelli Robson CSV results correlated with GCL thickness in all sectors, although the
219 association was not strong ($r < 0.5$). The superonasal ($r=0.40$, $p=0.010$), inferonasal ($r=0.40$,
220 $p=0.010$), inferior ($r=0.43$, $p=0.005$), superotemporal sector ($r=0.43$, $p=0.006$), and average
221 GCL+IPL ($r=0.45$, $p=0.004$) values had the highest correlations. The Pelli Robson results also
222 correlated with the thickness in different sectors of the RNFL (average, superior, and inferior
223 sectors). Measurements with the CSV 1000E at different spatial frequencies correlated
224 significantly with most GCL measurements. The superonasal ($r= 0.40$, $p= 0.013$) and
225 superotemporal ($r= 0.44$, $p= 0.006$) thickness, average GCL +IPL thickness ($r= 0.40$, $p= 0.012$),
226 and the minimum GCL + IPL ($r= 0.40$, $p=0.011$) at a spatial frequency of 6 cpd; and the
227 superotemporal ($r= 0.41$, $p= 0.01$) thickness and the minimum GCL + IPL thickness ($r= 0.43$,
228 $p=0.006$) at a spatial frequency of 18 cpd had the strongest correlations between CSV 1000E and
229 GCL thickness. Spatial frequencies of 6 cpd and 18 cpd were strongly correlated with average
230 macular thickness ($r= 0.79$, $p= 0.012$; $r= 0.77$, $p= 0.016$, respectively) and macular volume ($r=$
231 0.78 , $p= 0.013$; $r= 0.78$, $p= 0.014$, respectively, Figure 1).

232 Color vision assessed by the L'Anthony test was also associated with the structural parameters:
233 The C-index and CCI results were significantly correlated with all outer macular parameters and
234 most of the GCL measurements (see Table 4). A significant association between color vision and
235 the RNFL parameters was only found in isolated sectors. (see Table 4).

236

237

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

238

	L'Anthony color test					
	C-index	p	CCI	p	S-index	p
Macular thickness						
Central	-0.019	0.905	-0.059	0.716	-0.017	0.915
Inner superior	-0.146	0.369	-0.119	0.463	-0.167	0.302
Inner nasal	-0.055	0.735	-0.044	0.788	-0.040	0.807
Inner inferior	-0.073	0.654	-0.064	0.697	-0.074	0.645
Inner temporal	-0.049	0.764	-0.031	0.850	-0.126	0.439
Outer superior	-0.377	0.017	-0.380	0.015	-0.271	0.090
Outer nasal	-0.341	0.031	-0.323	0.042	-0.310	0.051
Outer inferior	-0.360	0.022	-0.353	0.025	-0.375	0.017
Outer temporal	-0.360	0.023	-0.361	0.022	-0.350	0.027
Macular average	-0.691	0.019	-0.657	0.028	-0.709	0.015
Macular volume	-0.686	0.020	-0.647	0.032	-0.709	0.015
Ganglion cell layer thickness						
Superior	-0.380	0.015	-0.369	0.019	-0.287	0.072
Superonasal	-0.383	0.015	-0.337	0.033	-0.350	0.027
Inferonasal	-0.338	0.033	-0.313	0.049	-0.268	0.094
Inferior	-0.341	0.031	-0.311	0.051	-0.282	0.078
Inferotemporal	-0.252	0.116	-0.263	0.101	-0.203	0.208
Temporal	-0.403	0.010	-0.437	0.005	-0.314	0.048
Average IPL+ GCL	-0.381	0.015	-0.358	0.023	-0.319	0.045
Minimum IPL+ GCL	-0.338	0.033	-0.326	0.040	-0.290	0.069

239

240 **Table 4**

241

242 The strongest correlation was between the average macular thickness and macular volume and
243 the L'Anthony CCI, C-index, and S-index results. No significant correlations were found
244 between the Farnsworth's test parameters and structural measurements.

The VA ETDRS results correlated strongly with average macular thickness and macular volume (see Table 5, Figures 2 and 3). There were significant but mild associations between the GCL parameters and VA at 100% (superonasal, inferonasal, and average GCL + IPL thickness, $r=-0.38$, $p=0.016$; $r=-0.35$, $p=0.016$; and $r=0.35$, $p=0.029$, respectively) and 2.50% (superonasal sector, $r=-0.36$, $p=0.023$).

	Macular thickness	P value	Macular volume	P value
VA ETDRS 100	-0.765	0.006	-0.761	0.007
VA ETDRS 1.25	-0.718	0.013	-0.715	0.013
VA ETDRS 2.50	-0.738	0.010	-0.729	0.011

Table 5

There was a significant correlation between Hoehn Yahr score and VA contrast level 2.50% ($r=0.48$, $p=0.040$), and CS measured with CSV 1000 at a space frequency of 12 cpd ($r=-0.59$, $p=0.038$). No correlations were detected between structural and disease severity parameters.

Discussion

In the present study, we evaluated the visual function parameters and assessed the association between visual dysfunction and morphologic changes in the retina of 37 patients with PD.

Parameters corresponding to VA at different contrast levels, and all CSV tests results were altered in PD patients in comparison with healthy subjects, prior to and after statistical correction for multiple tests. Moreover, contrast sensitivity was the most affected parameter in our study and correlated with most of the structural data. Color vision was measured with two different tests, the Farnsworth and L'Anthony 15 D tests. These tests provide information for

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

differentiating subjects with severe loss of color vision from those with milder color defects or normal color vision, and also can be used to evaluate acquired loss of color vision. In our study, only the L'Anthony Confusion Angle was significantly altered in PD patients. L'Anthony test is less saturated than the Farnsworth color test, thus it is designed to detect more subtle color deficiencies. Our patients performed worse than controls in both tests (higher C-index and S-index, reaching ranges similar to protanomalies) although these differences did not reach statistical significance as established by Bonferroni correction. L'Anthony S-index p value was <0.05, indicating that our patients had a (subtle) tendency to protanomaly (S-index of 1.95).

One important limitation of this study is that only one eye was tested per person. Some recent studies suggest asymmetrical involvement of the retina in PD and recommend the incorporation of both eyes of each patient in the study.[21] Thus, the diagnostic yield in this study may have been lowered by including a potentially lesser affected eye. In a similar way, including a randomly selected eye could be inappropriate for other neurological conditions, for example, a tumor compressing one optic nerve. However, incorporating both eyes of a patient may sometimes be controversial since a minimum symmetric structural and functional alterations could have been masked and generated a % of dependence between measurements.

Previous studies have indicated that PD patients lose foveal contrast sensitivity to patterns to which normal observers are most sensitive (i.e., requiring the least contrast for detection).[8,9] Ganglion cells in the retina show adaptation to visual contrast and pool visual inputs over their receptive fields through an array of parallel bipolar cells with smaller receptive fields.[22] The parvo- and magnocellular ganglion cells are located in the RGC layer and take two different pathways for the identification of color and contrast at different frequencies.[23] RGC loss (as observed using SD-OCT) was recently identified as the cause of visual impairment in patients

suffering from another neurodegenerative process, multiple sclerosis.[24] Thus, a similar process could be the cause of the contrast and color deficiencies in patients with PD. In addition, in the mammalian retina, color vision and contrast sensitivity are modulated through D1 and D2 receptors. These dopaminergic receptors are differentially located in the retinal layers and a complete lack of activation leads to signal dispersion and alterations in color vision and contrast sensitivity.[2]

Alteration of the retinal layers in PD was first demonstrated in 2004.[25] Since then, various studies have demonstrated different results.[3-5,25-28] Previous studies performed by our team confirmed that both macular thickness and the RNFL were affected in patients with PD, especially in the inferior and temporal quadrants.[4,5, 29] Moreover, Garcia-Martin et al demonstrated that the inner retinal layers were most affected in these patients, and that the GCL thickness was inversely correlated with disease duration and PD severity, and was predictive of axonal damage in these patients.[30] The present study included a smaller number of patients, which may have affected the significance of our results compared to previous studies. We could only detect a significant reduction in the minimum GCL+IPL thickness in PD patients compared to healthy subjects, after correction for multiple comparisons. However, we detected a clear tendency towards a reduction in the macular, RNFL, and GCL thicknesses. A significant reduction in the temporal sectors of the peripapillary RNFL thickness has been repeatedly observed by different groups [31, 32] and this reduction was also observed in the present study. Two recent studies, however, detected no differences in the peripapillary RNFL thickness of PD patients compared to healthy controls using SD-OCT [27,28] and one study only found significant differences in the nasal quadrant.[33] More studies are required to clarify these contradictory observations.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

In a previous study, we demonstrated that the retinal thickness corresponding to the papillomacular bundle (as measured with the Axonal Analytics software for Spectralis OCT) correlated ($r>0.70$) with some functional parameters (such as the mean defect and the pattern standard deviation of the automated perimetry) in patients with PD.[34] The GCL was not investigated at that time, however, and visual function parameters were reduced to perimetry and color vision measured with the Ishihara color test. The current study evaluated not only the RNFL but also the GCL thickness, and more visual function parameters were analyzed. The GCL correlated most with the visual function parameters: GCL thickness was directly associated with VA and CSV measured at all different spatial frequencies, and inversely correlated with the color vision indexes. Thus, GCL thinning is linked to color deficiencies, contrast sensitivity loss, and lower vision at different contrast levels in PD patients.

The degree of correlation is usually classified as low (<0.30), moderate ($0.30-0.70$), or strong (>0.70). Our results revealed a low and moderate degree of correlation between most parameters, consistent with findings in other neurodegenerative diseases.[35] Macular thickness and macular volume, however, were strongly associated with functional parameters (VA, CS, and L'Anthony CCI, C-index, and S-index). This strong association, to the best of our knowledge, has not been previously demonstrated in PD.

There are very few studies of the correlation between functional and structural parameters in PD patients. Adam et al [14] demonstrated a significant reduction in the inner retinal layer complex (RNFL + GCL + IPL) in PD patients, but no association with contrast sensitivity (measured with the Pelli Robson chart). A very recent study by Kaur et al [15] demonstrated a correlation between functional parameters and GCL thinning, consistent with our results. Kaur et al, however, found no significant alterations in VA or color vision in PD patients and the severity of

the disease was not correlated with structural parameters, in contrast to other studies that demonstrate an association between macular and GCL thickness and disease duration and severity.[29,30] Although the severity of the disease in our sample (based on the Hoehn Yahr scale) was similar to that in Kaur's study, the duration of the disease in our study was higher than that in Kaur's patients (13 years vs 5 years), which may account for some of the differences in the results between the two studies. These discrepancies (and similarities) support the need for more studies on this topic. Our results, together with previously published studies,[15, 30] suggest that the GCL could be a reliable indicator of structural alterations in the retina of PD patients, demonstrating a significant correlation with functional tests in these patients. The results of the present study have important implications for clinical diagnosis and functional deficits in patients with PD, and highlight the importance of visual function tests in the evaluation of these patients.

In conclusion, visual dysfunction was significantly correlated with morphologic parameters in PD patients. PD patients present with a reduction in GCL thickness, which is closely associated with visual dysfunction.

Contributorship:

V. Polo: Research project: organization. Statistical analysis and Manuscript: Review and critique.

M. Satue: Research project: Conception, design, organization and execution. Statistical analysis: Review and critique. Manuscript: Writing of the first draft, review and critique.

MJ Rodrigo: Research project: organization and execution. Statistical analysis: Review and

1
2
3 355 critique. Manuscript: Writing of the first draft, review and critique.
4
5
6 356 S. Otin: Research project: organization and execution. Statistical analysis: Review and critique.
7
8 357 Manuscript: review and critique.
9
10
11 358 R. Alarcia: Research project: organization and execution. Statistical analysis: Review and
12
13 359 critique. Manuscript: review and critique.
14
15
16 360 MP. Bambo: Research project: execution. Statistical analysis: Review and critique. Manuscript:
17
18 361 review and critique.
19
20
21 362 MI. Fuertes: Research project: execution. Statistical analysis: Review and critique. Manuscript:
22
23 363 review and critique.
24
25
26 364 JM. Larrosa: Research project: execution. Statistical analysis: Review and critique. Manuscript:
27
28 365 review and critique.
29
30
31 366 LE. Pablo: Research project: execution. Statistical analysis: Review and critique. Manuscript:
32
33 367 review and critique.
34
35
36 368 E. Garcia-Martin: Research project: Conception, design, organization and execution. Statistical
37
38 369 analysis: Design, execution, review and critique. Manuscript: Writing of the first draft, review
39
40 370 and critique.
41
42
43
44 371 **Competing interests and funding**
45
46
47 372 This research received no specific grant from any funding agency in the public, commercial or
48
49 373 not-for-profit sectors.
50
51
52 374 The authors disclose no conflict of interest.
53
54
55 375 **Data sharing**
56
57
58
59
60

376 All relevant data are included in this manuscript. No additional data available.

377

378

379

380

381

382

For peer review only

References

1. Bodis-Wollner I. Retinopathy in Parkinson disease. *J Neural Transm* 2009;116:1493-501.

2. Hajee ME, March WF, Lazzaro DR et al. Inner retinal layer thinning in Parkinson's disease. *Arch Ophthalmol* 2009;127:737-41.

3. Cubo E, Tedejo RP, Rodriguez Mendez V. Retina thickness in Parkinson's disease and essential tremor. *Mov Disord* 2010;25:2461-77.

4. Satue M, Garcia-Martin E, Fuertes I et al. Use of Fourier-domain OCT to detect retinal nerve fiber layer degeneration in Parkinson's disease patients. *Eye (Lond)* 2013;27:507-14.

5. Garcia-Martin E, Satue M, Fuertes I et al. Ability and reproducibility of Fourier domain optical coherence tomography to detect retinal nerve fiber layer atrophy in Parkinson's disease. *Ophthalmology* 2012;119:2161-7.

6. Fisher JB, Jacobs DA, Markowitz CE et al. Relation of visual function to retinal nerve fiber layer thickness in multiple sclerosis. *Ophthalmology* 2006;113:324.

7. Parisi V, Manni G, Spadaro M et al. Correlation between morphological and functional retinal impairment in multiple sclerosis patients. *Invest Ophthalmol Vis Sci* 1999;40:2520-7.

8. Bodis-Wollner I. Visual acuity and contrast sensitivity in patients with cerebral lesions. *Science* 1972;178:769-71.

9. Bodis-Wollner I, Diamond S. The measurement of spatial contrast sensitivity in cases of blurred vision associated with cerebral lesions. *Brain* 1976;99:695-710.

10. Price MJ, Feldman RG, Adelberg D et al. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. *Neurology* 1992;42:887-90.

11. Oh YS, Kim JS, Chung SW et al. Color vision in Parkinson's disease and essential tremor. European Journal of Neurology 2011;18: 577-83.
12. Hipp G, Diederichs NJ, Pieria V et al. Primary vision and facial emotion recognition in early Parkinson's disease. Journal of the Neurological Sciences 2014;338 :178-82.
13. Archibald NK, Clarke MP, Mosimann UP et al. Retinal thickness in Parkinson's disease. Parkinsonism Relat Disord 2011; 17(6):431-6.
14. Adam CR1, Shrier E, Ding Y et al. Correlation of inner retinal thickness evaluated by spectral-domain optical coherence tomography and contrast sensitivity in Parkinson disease. J Neuroophthalmol. 2013;33(2):137-42.
15. Kaur M, Saxena R, Singh D et al. Correlation Between Structural and Functional Retinal Changes in Parkinson Disease. J Neuroophthalmol 2015 [Epub ahead of print]
16. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol 1999;56:33-9.
17. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.
18. Ramaker C, Marinus J, Stiggelbout AM, et al. Systematic evaluation of rating scales for impairment and disability in Parkinson's disease. Mov Disord 2002;17(5):867-76.
19. Vingrys AJ, King-Smith PE. A quantitative scoring technique for panel tests of color vision. Invest Ophthalmol Vis Sci 1988;29(1):50-63.
20. Bowman AJ. A method for quantitative scoring of the Farnsworth panel D15. Acta Ophthalmologica 1982;60:907-16.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

21. Shrier EM, Adam CR, Spund B, Glazman S, Bodis-Wollner I. Interocular Asymmetry of Foveal Thickness in Parkinson Disease. *J Ophthalmol.* 2012; 2012:728457

22. Kim, KJ, Rieke, F. Temporal contrast adaptation in the input and output signals of salamander retinal ganglion cells. *J. Neurosci* 2001;21:287-99.

23. Laycock R, Crewther SG, Crewther DP. A role for the ‘magnocellular advantage’ in visual impairments in neurodevelopmental and psychiatric disorders. *Neurosci Biobehav Rev.* 2007;31:363-76.

24. Lampert EJ, Andorra M, Torres-Torres R, et al. Color vision impairment in multiple sclerosis points to retinal ganglion cell damage. *J Neurol.* 2015 [Epub ahead of print]

25. Inzelberg R, Ramirez JA, Nisipeanu P et al. Retinal nerve fiber layer thinning in Parkinson’s disease. *Vision Res* 2004;44:2793-7.

26. Altıntaş O, Işeri P, Ozkan B et al. Correlation between retinal morphological and functional findings and clinical severity in Parkinson’s disease. *Doc Ophthalmol* 2008;116:137-46.

27. Bittersohl D, Stemplewitz B, Keserü M et al. Detection of retinal changes in idiopathic Parkinson's disease using high-resolution optical coherence tomography and Heidelberg retina tomography. *Acta Ophthalmol.* 2015;93(7):e578-84.

28. Chorostecki J, Seraji-Bozorgzad N, Shah A et al. Characterization of retinal architecture in Parkinson's disease. *J Neurol Sci.* 2015;355(1-2):44-8.

29. Satue M, Seral M, Otin S et al. Retinal thinning and correlation with functional disability in patients with Parkinson's disease. *Br J Ophthalmol* 2014;98(3):350-5.

30. Garcia-Martin E, Larrosa JM, Polo V et al. Distribution of retinal layer atrophy in patients with Parkinson disease and association with disease severity and duration. *Am J Ophthalmol* 2014;157(2):470-8.
31. Sari ES, Koc R, Yazici A, Sahin G, Ermis SS. Ganglion cell-inner plexiform layer thickness in patients with Parkinson disease and association with disease severity and duration. *J Neuroophthalmol*. 2015;35(2):117-21.
32. La Morgia C, Barboni P, Rizzo G et al. Loss of temporal retinal nerve fibers in Parkinson disease: a mitochondrial pattern? *Eur J Neurol*. 2013;20(1):198-201
33. Bayhan HA, Aslan Bayhan S, Tanık N, Gürdal C. The association of spectral-domain optical coherence tomography determined ganglion cell complex parameters and disease severity in Parkinson's disease. *Curr Eye Res*. 2014;39(11):1117-22.
34. Satue M, Bambo M, Garcia-Martin E, et al. Correlation between function and structure of retinal nerve fiber layer in Parkinson disease. *Acta Ophthalmologica*. 2012;90:0.
35. Garcia-Martin E, Rodriguez-Mena D, Herrero R, et al. Neuro-ophthalmologic evaluation, quality of life and functional disability in MS patients. *Neurology* 2013;81:1-8.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Legends

Figure 1: Correlation between the average macular thickness and contrast sensitivity vision as measured with the CSV 1000E test, at a spatial frequency of 6 cycles per degree, in patients with Parkinson’s disease.

Figure 2: Correlation between the average macular thickness and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson’s disease.

Figure 3: Correlation between macular volume and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson’s disease.

Table 1: Epidemiologic and disease characteristics of patients with PD and healthy subjects, and statistical significance (P). Abbreviations: SD, standard deviation; UPDRS III, Unified Parkinson Disease Rating Scale part III.

Table 2: Mean and standard deviation (SD) of visual functional parameters in healthy controls and subjects with Parkinson disease. The asterisk indicates those values with statistical significance after Bonferroni correction for multiple tests (p<0.0125 for VA ETDRS 100, 2.50 and 1.25; p<0.0125 for Pelli Robson and CSV 1000E measurements; p<0.0083 for Farnsworth and L’Anthony tests). Abbreviations: VA, visual acuity; ETDRS, early treatment diabetic retinopathy study; cpd, cycles per degree; AC CCI, age corrected color confusion index; CCI, color confusion index; C-index, confusion index; Conf Angle, confusion angle; S-index, scatter

index; PD, Parkinson disease.

Table 3: Mean and standard deviation (SD) of structural parameters (retinal nerve fiber layer, ganglion cell layer and macular thicknesses) obtained with the Cirrus HD optical coherence tomography device in healthy controls and subjects with Parkinson disease. The asterisk indicates those values with statistical significance after Bonferroni correction for multiple tests ($p < 0.0055$ for macular measurements; $p < 0.0062$ for ganglion cell measurements and $p < 0.01$ for RNFL measurements). Abbreviations: IPL, inner plexiform layer; GCL, ganglion cell layer; RNFL, retinal nerve fiber layer; HD, high definition.

Table 4: Correlation between macular and ganglion cell layer structural measurements and color vision evaluated with L'Anthony color test in patients with Parkinson disease. Data in bold type correspond to statistically significant correlations (p value < 0.05). Abbreviations: GCL, ganglion cell layer; IPL, inner plexiform layer; C-index, Confusion index; CCI, color confusion index; S-index, Scatter index.

Table 5: Correlation between visual acuity measured with ETDRS chart at different levels of contrast (in %) and macular structural measurements (thickness and volume) in patients with Parkinson disease. Correlation data in bold type are statistically significant (p value < 0.05). Abbreviations: VA, visual acuity; ETDRS, Early Treatment Diabetic Retinopathy Study.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

508

509

For peer review only




Figure 1: Correlation between the average macular thickness and contrast sensitivity vision as measured with the CSV 1000E test, at a spatial frequency of 6 cycles per degree, in patients with Parkinson's disease. 108x83mm (300 x 300 DPI)




Figure 2: Correlation between the average macular thickness and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson’s disease.
118x100mm (300 x 300 DPI)




Figure 3: Correlation between macular volume and visual acuity as measured with ETDRS optotype at a contrast level of 100% in patients with Parkinson's disease.
119x102mm (300 x 300 DPI)

STROBE Statement—Checklist of items that should be included in reports of *case-control studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study’s design with a commonly used term in the title or the abstract Check. This included in the abstract, methods, line 1
		(b) Provide in the abstract an informative and balanced summary of what was done and what was found Check. This is included in the abstract. Methods, from line 2 to results section line 9
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported Check. This is included in the introduction. Paragraph 2.
Objectives	3	State specific objectives, including any prespecified hypotheses Check. This is included in the introduction. Paragraph 3.
Methods		
Study design	4	Present key elements of study design early in the paper Check. This is included in Methods, paragraph 1-3.
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection Check. This is included in Methods, paragraph 1-3.
Participants	6	(a) Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls Check. This is included in Methods, paragraph 2
		(b) For matched studies, give matching criteria and the number of controls per case Check. This is included in Methods, paragraph 1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable Check. Outcomes and variables are explained in Methods, paragraphs 4-8
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Check. Details of measurements are included in paragraphs 4-8.
Bias	9	Describe any efforts to address potential sources of bias Check. This is included in paragraph 8, line 3-4.
Study size	10	Explain how the study size was arrived at
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why Check. Quantitative variables are explained in Methods, paragraphs 4-8
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding. Check. This is included in methods, paragraph 9
		(b) Describe any methods used to examine subgroups and interactions. Not applicable.
		(c) Explain how missing data were addressed Not applicable
		(d) If applicable, explain how matching of cases and controls was addressed Not applicable
		(e) Describe any sensitivity analyses Not applicable

Results

Participants	13*	<p>(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed</p> <hr/> <p>(b) Give reasons for non-participation at each stage</p> <hr/> <p>(c) Consider use of a flow diagram</p> <p>This is a cross sectional study. Inclusion criteria were explained in methods. All eligible subjects were included in the study (37) as already explained, all completed the evaluation.</p>
Descriptive data	14*	<p>(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders Check. This is included in Results, paragraph 1-2 and table 1.</p> <hr/> <p>(b) Indicate number of participants with missing data for each variable of interest</p> <p>Not applicable.</p>
Outcome data	15*	<p>Report numbers in each exposure category, or summary measures of exposure</p> <p>Check. Numbers and results of each variable are included in results.</p>
Main results	16	<p>(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included</p> <p>Check. Main results include statistical results prior and post multiple comparisons adjustment.</p> <hr/> <p>(b) Report category boundaries when continuous variables were categorized Check. Category of correlation is explained in discussion, paragraph 5</p> <hr/> <p>(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period Not applicable</p>

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses Not applicable
Discussion		
Key results	18	Summarise key results with reference to study objectives Check. This is included in results, paragraph 1.
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias Check, this is mentioned in paragraph 3 and 6.
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence Check. This is included and discussed along the discussion section.
Generalisability	21	Discuss the generalisability (external validity) of the study results Check. This is included and discussed along the discussion section
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based Check. Not applicable.

*Give information separately for cases and controls.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.